<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS Comput Biol</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">ploscomp</journal-id>
<journal-title-group>
<journal-title>PLOS Computational Biology</journal-title>
</journal-title-group>
<issn pub-type="ppub">1553-734X</issn>
<issn pub-type="epub">1553-7358</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">PCOMPBIOL-D-17-00190</article-id>
<article-id pub-id-type="doi">10.1371/journal.pcbi.1005719</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Immune physiology</subject><subj-group><subject>Antibodies</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Immune physiology</subject><subj-group><subject>Antibodies</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune system proteins</subject><subj-group><subject>Antibodies</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune system proteins</subject><subj-group><subject>Antibodies</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Immune system proteins</subject><subj-group><subject>Antibodies</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Infectious diseases</subject><subj-group><subject>Viral diseases</subject><subj-group><subject>Cytomegalovirus infection</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Epidemiology</subject><subj-group><subject>Infectious disease epidemiology</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Infectious diseases</subject><subj-group><subject>Infectious disease epidemiology</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>DNA viruses</subject><subj-group><subject>Herpesviruses</subject><subj-group><subject>Human cytomegalovirus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical microbiology</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Herpesviruses</subject><subj-group><subject>Human cytomegalovirus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Herpesviruses</subject><subj-group><subject>Human cytomegalovirus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Herpesviruses</subject><subj-group><subject>Human cytomegalovirus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Serology</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Immunologic techniques</subject><subj-group><subject>Immunoassays</subject><subj-group><subject>Enzyme-linked immunoassays</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Vaccination and immunization</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Vaccination and immunization</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Public and occupational health</subject><subj-group><subject>Preventive medicine</subject><subj-group><subject>Vaccination and immunization</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and places</subject><subj-group><subject>Population groupings</subject><subj-group><subject>Age groups</subject></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Infectious reactivation of cytomegalovirus explaining age- and sex-specific patterns of seroprevalence</article-title>
<alt-title alt-title-type="running-head">Infectious reactivation of cytomegalovirus</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-0841-2400</contrib-id>
<name name-style="western">
<surname>van Boven</surname> <given-names>Michiel</given-names></name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Software</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>van de Kassteele</surname> <given-names>Jan</given-names></name>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Software</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Korndewal</surname> <given-names>Marjolein J.</given-names></name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-7504-9947</contrib-id>
<name name-style="western">
<surname>van Dorp</surname> <given-names>Christiaan H.</given-names></name>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Software</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Kretzschmar</surname> <given-names>Mirjam</given-names></name>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff004"><sup>4</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-6759-3539</contrib-id>
<name name-style="western">
<surname>van der Klis</surname> <given-names>Fiona</given-names></name>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>de Melker</surname> <given-names>Hester E.</given-names></name>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Vossen</surname> <given-names>Ann C.</given-names></name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>van Baarle</surname> <given-names>Debbie</given-names></name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
</contrib-group>
<aff id="aff001">
<label>1</label>
<addr-line>Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands</addr-line>
</aff>
<aff id="aff002">
<label>2</label>
<addr-line>Leiden University Medical Center, Department of Medical Microbiology, Leiden, the Netherlands</addr-line>
</aff>
<aff id="aff003">
<label>3</label>
<addr-line>Theoretical Biology and Bioinformatics, Utrecht University, Utrecht, the Netherlands</addr-line>
</aff>
<aff id="aff004">
<label>4</label>
<addr-line>Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands</addr-line>
</aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Alizon</surname> <given-names>Samuel</given-names></name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1">
<addr-line>CNRS, FRANCE</addr-line>
</aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">michiel.van.boven@rivm.nl</email></corresp>
</author-notes>
<pub-date pub-type="collection">
<month>9</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>26</day>
<month>9</month>
<year>2017</year>
</pub-date>
<volume>13</volume>
<issue>9</issue>
<elocation-id>e1005719</elocation-id>
<history>
<date date-type="received">
<day>3</day>
<month>2</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>2</day>
<month>8</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-year>2017</copyright-year>
<copyright-holder>van Boven et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pcbi.1005719"/>
<abstract>
<p>Human cytomegalovirus (CMV) is a herpes virus with poorly understood transmission dynamics. Person-to-person transmission is thought to occur primarily through transfer of saliva or urine, but no quantitative estimates are available for the contribution of different infection routes. Using data from a large population-based serological study (n = 5,179), we provide quantitative estimates of key epidemiological parameters, including the transmissibility of primary infection, reactivation, and re-infection. Mixture models are fitted to age- and sex-specific antibody response data from the Netherlands, showing that the data can be described by a model with three distributions of antibody measurements, i.e. uninfected, infected, and infected with increased antibody concentration. Estimates of seroprevalence increase gradually with age, such that at 80 years 73% (95%CrI: 64%-78%) of females and 62% (95%CrI: 55%-68%) of males are infected, while 57% (95%CrI: 47%-67%) of females and 37% (95%CrI: 28%-46%) of males have increased antibody concentration. Merging the statistical analyses with transmission models, we find that models with infectious reactivation (i.e. reactivation that can lead to the virus being transmitted to a novel host) fit the data significantly better than models without infectious reactivation. Estimated reactivation rates increase from low values in children to 2%-4% per year in women older than 50 years. The results advance a hypothesis in which transmission from adults after infectious reactivation is a key driver of transmission. We discuss the implications for control strategies aimed at reducing CMV infection in vulnerable groups.</p>
</abstract>
<abstract abstract-type="summary">
<title>Author summary</title>
<p>Human cytomegalovirus (CMV) is a herpes virus causing lifelong infection. In high-income countries, the probability of infection increases gradually with age such that at old age up to 100% of the population is infected. CMV is thought to be transmitted mainly by transfer of saliva or urine, but little quantitative evidence is available about the transmission dynamics. We analyze serological data to estimate age- and sex-specific rates of infection, re-infection, and reactivation. The analyses show that infectious reactivation (i.e. reactivation of the virus in an infected person that is sufficient for it to be transmitted to another person) is essential to explain the data. We propose that infectious reactivation in adults is an important driver of transmission of CMV.</p>
</abstract>
<funding-group>
<award-group id="award001">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100002999</institution-id>
<institution>Ministerie van Volksgezondheid, Welzijn en Sport</institution>
</institution-wrap>
</funding-source>
</award-group>
<award-group id="award002">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100003246</institution-id>
<institution>Nederlandse Organisatie voor Wetenschappelijk Onderzoek</institution>
</institution-wrap>
</funding-source>
<award-id>645.000.002</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>van Boven</surname> <given-names>Michiel</given-names></name>
</principal-award-recipient>
</award-group>
<award-group id="award003">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100003246</institution-id>
<institution>Nederlandse Organisatie voor Wetenschappelijk Onderzoek</institution>
</institution-wrap>
</funding-source>
<award-id>823.02.014</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>van Baarle</surname> <given-names>Debbie</given-names></name>
</principal-award-recipient>
</award-group>
<funding-statement>This work was supported by the Dutch Ministry of Health, Welfare and Sport and the Netherlands Organisation for Scientific Research (grants 645.000.002 and 823.02.014). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
</funding-group>
<counts>
<fig-count count="6"/>
<table-count count="2"/>
<page-count count="18"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>PLOS Publication Stage</meta-name>
<meta-value>vor-update-to-uncorrected-proof</meta-value>
</custom-meta>
<custom-meta>
<meta-name>Publication Update</meta-name>
<meta-value>2017-10-06</meta-value>
</custom-meta>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>Data are available at GitHub (github.com/mvboven/cmv-serology).</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec001" sec-type="intro">
<title>Introduction</title>
<p>Human cytomegalovirus (CMV) is a highly prevalent herpesvirus that infects between 30% and 100% of persons in populations throughout the world [<xref ref-type="bibr" rid="pcbi.1005719.ref001">1</xref>]. Usually thought to be a relatively benign persistent infection, CMV is able to cause serious disease in the immunocompromised and offspring of pregnant women with an active infection [<xref ref-type="bibr" rid="pcbi.1005719.ref002">2</xref>–<xref ref-type="bibr" rid="pcbi.1005719.ref005">5</xref>]. CMV also has been implicated in a variety of diseases in healthy persons [<xref ref-type="bibr" rid="pcbi.1005719.ref004">4</xref>, <xref ref-type="bibr" rid="pcbi.1005719.ref006">6</xref>–<xref ref-type="bibr" rid="pcbi.1005719.ref008">8</xref>], and plays a role in aging of the immune system [<xref ref-type="bibr" rid="pcbi.1005719.ref009">9</xref>–<xref ref-type="bibr" rid="pcbi.1005719.ref012">12</xref>], perhaps thereby reducing the effectiveness of vaccination in older persons [<xref ref-type="bibr" rid="pcbi.1005719.ref013">13</xref>–<xref ref-type="bibr" rid="pcbi.1005719.ref015">15</xref>].</p>
<p>Although the importance of CMV to public health is acknowledged, and even though the development and registration of a vaccine has been declared a priority [<xref ref-type="bibr" rid="pcbi.1005719.ref016">16</xref>, <xref ref-type="bibr" rid="pcbi.1005719.ref017">17</xref>], little quantitative information is available on the transmission dynamics of CMV. At present, the only population-level data derive from serological studies, aiming to uncover which part of the population is infected at what age. These studies show that i) a sizable fraction of infants is infected perinatally (before 6 months of age), ii) seroprevalence increases gradually with age and is usually higher in females than in males, and iii) the probability of seropositivity is associated with both ethnicity and socioeconomic status, with non-western ethnicity and lower socioeconomic status being associated with higher rates of seropositivity [<xref ref-type="bibr" rid="pcbi.1005719.ref001">1</xref>, <xref ref-type="bibr" rid="pcbi.1005719.ref018">18</xref>–<xref ref-type="bibr" rid="pcbi.1005719.ref021">21</xref>].</p>
<p>CMV infection has a profound impact on the human immune system. Most prominently, it is able to mould the T cell immune repertoire, in particular by expansion of the CMV-specific CD8+ memory T cell pool, a phenomenon called memory inflation [<xref ref-type="bibr" rid="pcbi.1005719.ref012">12</xref>]. Similar result have been found for memory B cell immunity [<xref ref-type="bibr" rid="pcbi.1005719.ref022">22</xref>]. With regard to humoral immune responses, high levels of CMV-specific IgG antibodies are increasingly considered a biomarker for lack of control by the immune system of the host, and have been associated with high probability of reactivation ([<xref ref-type="bibr" rid="pcbi.1005719.ref023">23</xref>, <xref ref-type="bibr" rid="pcbi.1005719.ref024">24</xref>], see [<xref ref-type="bibr" rid="pcbi.1005719.ref012">12</xref>] and references therein). In view of this, it is not surprising that evidence is accumulating of an association between high levels of CMV-specific IgG antibodies, inflammation, vascular disease, and mortality [<xref ref-type="bibr" rid="pcbi.1005719.ref006">6</xref>, <xref ref-type="bibr" rid="pcbi.1005719.ref007">7</xref>].</p>
<p>Person-to-person transmission of CMV from an infected to an uninfected person can occur from a primary infected person, or from a person who is experiencing a reactivation episode or from a person who has been reinfected [<xref ref-type="bibr" rid="pcbi.1005719.ref004">4</xref>]. Here, we analyze data from a large-scale serological study to obtain quantitative estimates of the relative importance of these transmission routes [<xref ref-type="bibr" rid="pcbi.1005719.ref021">21</xref>]. We fit mixture models linked to age- and sex-specific transmission models to the data to study the ability of different hypotheses explaining the serological data. Specifically, we quantify the incidence and transmissibility of primary infection, re-infection, and reactivation. Throughout, our premise is that measurements of antibody concentrations provide information on whether or not a person has been infected, and whether or not re-infection or reactivation have occurred. Persons with low measurements are considered uninfected (susceptible), while persons with intermediate and high antibody concentrations are infected with and without subsequent re-infection or reactivation, respectively.</p>
<p>The analyses show that infectious reactivation in adults is necessary to explain the data, and is expected to be an important driver of transmission. The results have implications for control of CMV by vaccination, but also in the broader context of T cell immune memory inflation, vascular disease, and immunosenescence [<xref ref-type="bibr" rid="pcbi.1005719.ref012">12</xref>, <xref ref-type="bibr" rid="pcbi.1005719.ref025">25</xref>, <xref ref-type="bibr" rid="pcbi.1005719.ref026">26</xref>].</p>
</sec>
<sec id="sec002" sec-type="materials|methods">
<title>Methods</title>
<sec id="sec003">
<title>Ethics statement</title>
<p>The study was approved by the Medical Ethics Testing Committee of the foundation of therapeutic evaluation of medicines (METC-STEG) in Almere, the Netherlands (clinical trial number: ISRCTN 20164309). All participants or their legal representatives had given written informed consent.</p>
</sec>
<sec id="sec004">
<title>Study design</title>
<p>The analyses make use of sera from a cross-sectional population-based study carried out in the Netherlands in 2006-2007. Details have been published elsewhere [<xref ref-type="bibr" rid="pcbi.1005719.ref021">21</xref>, <xref ref-type="bibr" rid="pcbi.1005719.ref027">27</xref>]. Briefly, 40 municipalities distributed over five geographic regions of the Netherlands were randomly selected with probabilities proportional to their population size, and an age-stratified sample was drawn from the population register. A total of 19,781 persons were invited to complete a questionnaire and donate a blood sample. Serum samples and questionnaires were obtained from 6,382 participants. To exclude the interference of maternal antibodies, we restrict analyses to sera from persons older than 6 months (6,215 samples). We further select Dutch persons and migrants of Western ethnicity to preclude confounding by ethnicity (5,179 samples) and stratify the data by sex [<xref ref-type="bibr" rid="pcbi.1005719.ref021">21</xref>], yielding 2,842 and 2,337 samples from female and male participants, respectively. The data are available at github.com/mvboven/cmv-serology.</p>
</sec>
<sec id="sec005">
<title>Antibody assay</title>
<p>We use the ETI-CYTOK-G PLUS (DiaSorin, Saluggia, Italy) Elisa to detect CMV-specific IgG antibodies. The assay yields continuous measurements (henceforth called ‘antibody concentration’). A small number of samples is right-censored (140 persons). We perform a Box-Cox transformation of the data (λ = 0.3), yielding a distribution of low antibody concentrations (-2.8&lt; <italic>x</italic> ≤-0.5) that is approximately normal. According to the provider of the assay, samples with (transformed) measurement lower than -0.8 U/ml should be considered uninfected, while samples with measurement greater or equal than -0.8 U/ml should be classified as infected. Right-censoring is applied to the 140 samples above the upper limit of 3.41 U/ml. The data with model fit (see below) are shown in <xref ref-type="fig" rid="pcbi.1005719.g001">Fig 1</xref>.</p>
<fig id="pcbi.1005719.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1005719.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Data and model fit.</title>
<p>Data (histograms) and model fit (lines) of IgG antibody measurements by age group and sex. Left- and right-hand panels show results for females (purple) and males (brown), respectively. The leftmost bars at -2.9 contain samples that are assumed uninfected, and the rightmost bars at 4.5 contain samples that are right-censored (with concentration &gt;3.41 U/ml; <xref ref-type="sec" rid="sec002">Methods</xref>). Insets show the age group and number of samples.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005719.g001" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec006">
<title>Mixture model</title>
<p>The data are analyzed statistically using a mixture model with sex- and age-specific mixing functions. We distinguish three distributions, describing samples of low (susceptible, S), intermediate (latently infected, L), and high (latently infected with increased antibodies, B) antibody concentrations. The L and B distributions are modeled using normal distributions with means and standard deviations independent of age and sex. The S distribution is modeled by a mixture of a spike and a normal distribution (an inflated normal distribution), as there appears a spike at -2.91 U/ml in the data (263 persons). In this way, samples with concentration at the spike belong to the susceptible component with probability 1.</p>
<p>We model the probability of each of the three outcomes in terms of log-odds, taking the probability of being in the S component as reference. This allows us to write the log-odds of being in component L or B as linear functions of age and sex. The design matrix of the resulting multinomial logistic model consists of natural cubic splines with interior knots at 20, 40 and 60 years and boundary knots at 0 and 80 years. Hence, the mixing functions (prevalences) have flexible shape, which allows these to be optimally informed by the data. In the results, sex is put in the model as main effect, as analyses show no improvement in fit when including age by sex interaction.</p>
<p>We estimate parameters in a Bayesian framework using R and JAGS [<xref ref-type="bibr" rid="pcbi.1005719.ref028">28</xref>, <xref ref-type="bibr" rid="pcbi.1005719.ref029">29</xref>]. Non-informative normal prior distributions are set on the means of the three component distributions (<inline-formula id="pcbi.1005719.e001"><alternatives><graphic id="pcbi.1005719.e001g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005719.e001" xlink:type="simple"/><mml:math display="inline" id="M1"><mml:mrow><mml:mi mathvariant="script">N</mml:mi> <mml:mo>(</mml:mo> <mml:mn>0</mml:mn> <mml:mo>,</mml:mo> <mml:mn>0</mml:mn> <mml:mo>.</mml:mo> <mml:mn>001</mml:mn> <mml:mo>)</mml:mo></mml:mrow></mml:math></alternatives></inline-formula>) (mean and precision). Label switching is prevented by prior ordering of the means. The precisions of the components are given flat Gamma prior distributions (Γ(0.5, 0.005)). The spline parameters are also given non-informative normal prior distributions (<inline-formula id="pcbi.1005719.e002"><alternatives><graphic id="pcbi.1005719.e002g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005719.e002" xlink:type="simple"/><mml:math display="inline" id="M2"><mml:mrow><mml:mi mathvariant="script">N</mml:mi> <mml:mo>(</mml:mo> <mml:mn>0</mml:mn> <mml:mo>,</mml:mo> <mml:mn>0</mml:mn> <mml:mo>.</mml:mo> <mml:mn>001</mml:mn> <mml:mo>)</mml:mo></mml:mrow></mml:math></alternatives></inline-formula>). We apply a QR-decomposition to the design matrix to improve mixing and run 10 MCMC chains in parallel, yielding a total of 10,000 samples. We apply an 1/10 thinning to give a well-mixed 1,000 samples from the posterior distribution.</p>
</sec>
<sec id="sec007">
<title>Transmission model and scenarios</title>
<p>Next to the mixture model analyses, we estimate parameters of transmission models to investigate the ability of different transmission hypotheses explaining the data. To facilitate comparison between transmission models, take the medians of the estimated mixture distributions as input. In line with the above, we focus on a sex- and age-structured model in which persons are probabilistically classified as uninfected (S), latently infected (L), and latently infected after reactivation or re-infection (B). As the infectious period is short relative to the lifespan of the host (weeks versus decades), the infectious periods are modeled implicitly using the short-disease approximation [<xref ref-type="bibr" rid="pcbi.1005719.ref030">30</xref>]. Further, we focus on the endemic equilibrium of the transmission model so that all variables are time-independent [<xref ref-type="bibr" rid="pcbi.1005719.ref030">30</xref>, <xref ref-type="bibr" rid="pcbi.1005719.ref031">31</xref>]. <xref ref-type="fig" rid="pcbi.1005719.g002">Fig 2</xref> shows a schematic of the model. For sexes <italic>i</italic> ∈ {♀, ♂}, the differential equations for the age-specific relative frequencies <italic>S</italic>(<italic>a</italic>), <italic>L</italic>(<italic>a</italic>), and <italic>B</italic>(<italic>a</italic>) (<italic>S</italic>(<italic>a</italic>) + <italic>L</italic>(<italic>a</italic>) + <italic>B</italic>(<italic>a</italic>) = 1) are given by
<disp-formula id="pcbi.1005719.e003"><alternatives><graphic id="pcbi.1005719.e003g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005719.e003" xlink:type="simple"/><mml:math display="block" id="M3"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi> <mml:msup><mml:mi>S</mml:mi> <mml:mi>i</mml:mi></mml:msup> <mml:mrow><mml:mo>(</mml:mo> <mml:mi>a</mml:mi> <mml:mo>)</mml:mo></mml:mrow></mml:mrow> <mml:mrow><mml:mi>d</mml:mi> <mml:mi>a</mml:mi></mml:mrow></mml:mfrac></mml:mtd> <mml:mtd columnalign="left"><mml:mrow><mml:mo>=</mml:mo> <mml:mo>-</mml:mo> <mml:msup><mml:mo>λ</mml:mo> <mml:mi>i</mml:mi></mml:msup> <mml:mrow><mml:mo>(</mml:mo> <mml:mi>a</mml:mi> <mml:mo>)</mml:mo></mml:mrow> <mml:msup><mml:mi>S</mml:mi> <mml:mi>i</mml:mi></mml:msup> <mml:mrow><mml:mo>(</mml:mo> <mml:mi>a</mml:mi> <mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mtd></mml:mtr> <mml:mtr><mml:mtd columnalign="right"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi> <mml:msup><mml:mi>L</mml:mi> <mml:mi>i</mml:mi></mml:msup> <mml:mrow><mml:mo>(</mml:mo> <mml:mi>a</mml:mi> <mml:mo>)</mml:mo></mml:mrow></mml:mrow> <mml:mrow><mml:mi>d</mml:mi> <mml:mi>a</mml:mi></mml:mrow></mml:mfrac></mml:mtd> <mml:mtd columnalign="left"><mml:mrow><mml:mo>=</mml:mo> <mml:msup><mml:mo>λ</mml:mo> <mml:mi>i</mml:mi></mml:msup> <mml:mrow><mml:mo>(</mml:mo> <mml:mi>a</mml:mi> <mml:mo>)</mml:mo></mml:mrow> <mml:msup><mml:mi>S</mml:mi> <mml:mi>i</mml:mi></mml:msup> <mml:mrow><mml:mo>(</mml:mo> <mml:mi>a</mml:mi> <mml:mo>)</mml:mo></mml:mrow> <mml:mo>-</mml:mo> <mml:mo>(</mml:mo> <mml:msup><mml:mi>ρ</mml:mi> <mml:mi>i</mml:mi></mml:msup> <mml:mrow><mml:mo>(</mml:mo> <mml:mi>a</mml:mi> <mml:mo>)</mml:mo></mml:mrow> <mml:mo>+</mml:mo> <mml:mi>z</mml:mi> <mml:mspace width="3.33333pt"/><mml:msup><mml:mo>λ</mml:mo> <mml:mi>i</mml:mi></mml:msup> <mml:mrow><mml:mo>(</mml:mo> <mml:mi>a</mml:mi> <mml:mo>)</mml:mo></mml:mrow> <mml:mo>)</mml:mo> <mml:msup><mml:mi>L</mml:mi> <mml:mi>i</mml:mi></mml:msup> <mml:mrow><mml:mo>(</mml:mo> <mml:mi>a</mml:mi> <mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mtd></mml:mtr> <mml:mtr><mml:mtd columnalign="right"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi> <mml:msup><mml:mi>B</mml:mi> <mml:mi>i</mml:mi></mml:msup> <mml:mrow><mml:mo>(</mml:mo> <mml:mi>a</mml:mi> <mml:mo>)</mml:mo></mml:mrow></mml:mrow> <mml:mrow><mml:mi>d</mml:mi> <mml:mi>a</mml:mi></mml:mrow></mml:mfrac></mml:mtd> <mml:mtd columnalign="left"><mml:mrow><mml:mo>=</mml:mo> <mml:mo>(</mml:mo> <mml:msup><mml:mi>ρ</mml:mi> <mml:mi>i</mml:mi></mml:msup> <mml:mrow><mml:mo>(</mml:mo> <mml:mi>a</mml:mi> <mml:mo>)</mml:mo></mml:mrow> <mml:mo>+</mml:mo> <mml:mi>z</mml:mi> <mml:mspace width="3.33333pt"/><mml:msup><mml:mo>λ</mml:mo> <mml:mi>i</mml:mi></mml:msup> <mml:mrow><mml:mo>(</mml:mo> <mml:mi>a</mml:mi> <mml:mo>)</mml:mo></mml:mrow> <mml:mo>)</mml:mo> <mml:msup><mml:mi>L</mml:mi> <mml:mi>i</mml:mi></mml:msup> <mml:mrow><mml:mo>(</mml:mo> <mml:mi>a</mml:mi> <mml:mo>)</mml:mo></mml:mrow> <mml:mspace width="3.33333pt"/><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives> <label>(1)</label></disp-formula>
with forces of infection
<disp-formula id="pcbi.1005719.e004"><alternatives><graphic id="pcbi.1005719.e004g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005719.e004" xlink:type="simple"/><mml:math display="block" id="M4"><mml:mrow><mml:mrow><mml:msup><mml:mo>λ</mml:mo> <mml:mi>i</mml:mi></mml:msup> <mml:mrow><mml:mo>(</mml:mo> <mml:mi>a</mml:mi> <mml:mo>)</mml:mo></mml:mrow> <mml:mo>=</mml:mo></mml:mrow> <mml:mrow><mml:munder><mml:mstyle displaystyle="true" mathsize="140%"><mml:mo>∑</mml:mo></mml:mstyle> <mml:mrow><mml:mi>j</mml:mi> <mml:mo>∈</mml:mo> <mml:mrow><mml:mo>{</mml:mo> <mml:mrow><mml:mo>♀</mml:mo> <mml:mo>,</mml:mo> <mml:mo>♂</mml:mo></mml:mrow> <mml:mo>}</mml:mo></mml:mrow></mml:mrow></mml:munder> <mml:msubsup><mml:mo>∫</mml:mo> <mml:mn>0</mml:mn> <mml:mi>M</mml:mi></mml:msubsup> <mml:msup><mml:mi>c</mml:mi> <mml:mrow><mml:mi>i</mml:mi> <mml:mi>j</mml:mi></mml:mrow></mml:msup> <mml:mrow><mml:mo>(</mml:mo> <mml:mrow><mml:mi>a</mml:mi> <mml:mo>,</mml:mo> <mml:msup><mml:mi>a</mml:mi> <mml:mo>′</mml:mo></mml:msup></mml:mrow> <mml:mo>)</mml:mo></mml:mrow> <mml:mrow><mml:mo>(</mml:mo> <mml:mrow><mml:msub><mml:mi>β</mml:mi> <mml:mn>1</mml:mn></mml:msub> <mml:msup><mml:mo>λ</mml:mo> <mml:mi>j</mml:mi></mml:msup> <mml:mrow><mml:mo>(</mml:mo> <mml:msup><mml:mi>a</mml:mi> <mml:mo>′</mml:mo></mml:msup> <mml:mo>)</mml:mo></mml:mrow> <mml:msup><mml:mi>S</mml:mi> <mml:mi>j</mml:mi></mml:msup> <mml:mrow><mml:mo>(</mml:mo> <mml:msup><mml:mi>a</mml:mi> <mml:mo>′</mml:mo></mml:msup> <mml:mo>)</mml:mo></mml:mrow> <mml:mo>+</mml:mo> <mml:msub><mml:mi>β</mml:mi> <mml:mn>2</mml:mn></mml:msub> <mml:mrow><mml:mo>(</mml:mo> <mml:mrow><mml:msup><mml:mi>ρ</mml:mi> <mml:mi>j</mml:mi></mml:msup> <mml:mrow><mml:mo>(</mml:mo> <mml:msup><mml:mi>a</mml:mi> <mml:mo>′</mml:mo></mml:msup> <mml:mo>)</mml:mo></mml:mrow> <mml:mo>+</mml:mo> <mml:mi>z</mml:mi> <mml:msup><mml:mo>λ</mml:mo> <mml:mi>j</mml:mi></mml:msup> <mml:mrow><mml:mo>(</mml:mo> <mml:msup><mml:mi>a</mml:mi> <mml:mo>′</mml:mo></mml:msup> <mml:mo>)</mml:mo></mml:mrow></mml:mrow> <mml:mo>)</mml:mo></mml:mrow> <mml:msup><mml:mi>L</mml:mi> <mml:mi>j</mml:mi></mml:msup> <mml:mrow><mml:mo>(</mml:mo> <mml:msup><mml:mi>a</mml:mi> <mml:mo>′</mml:mo></mml:msup> <mml:mo>)</mml:mo></mml:mrow></mml:mrow> <mml:mo>)</mml:mo></mml:mrow> <mml:mi>d</mml:mi> <mml:msup><mml:mi>a</mml:mi> <mml:mo>′</mml:mo></mml:msup> <mml:mspace width="1pt"/><mml:mo>.</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives> <label>(2)</label></disp-formula></p>
<fig id="pcbi.1005719.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1005719.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Schematic of the transmission model.</title>
<p><italic>S</italic><sup><italic>i</italic></sup>(<italic>a</italic>) denotes the proportion of uninfected persons of age <italic>a</italic> and sex <italic>i</italic> (<italic>i</italic> ∈ {♀, ♂}), and <italic>L</italic><sup><italic>i</italic></sup>(<italic>a</italic>) and <italic>B</italic><sup><italic>i</italic></sup>(<italic>a</italic>) are the corresponding proportions of infected persons without and with increased antibodies, respectively. The infection and re-infection rates are given by λ<sup><italic>i</italic></sup>(<italic>a</italic>) and <italic>zλ</italic><sup><italic>i</italic></sup>(<italic>a</italic>), and the reactivation rates are given by <italic>ρ</italic><sup><italic>i</italic></sup>(<italic>a</italic>). We consider model scenarios with and without reactivation/re-infection in the <italic>B</italic> compartment (i.e. including or excluding the loop to the right of <italic>B</italic>).</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005719.g002" xlink:type="simple"/>
</fig>
<p>In Eqs <xref ref-type="disp-formula" rid="pcbi.1005719.e003">(1)</xref> and <xref ref-type="disp-formula" rid="pcbi.1005719.e004">(2)</xref>, <italic>zλ</italic><sup><italic>j</italic></sup>(<italic>a</italic>) and <italic>ρ</italic><sup><italic>j</italic></sup>(<italic>a</italic>) are the age-specific re-infection and reactivation rates, <italic>z</italic> is the susceptibility to re-infection of latently infected persons relative to the susceptibility of uninfected persons (0 ≤ <italic>z</italic> ≤ 1), <italic>c</italic><sup><italic>ij</italic></sup>(<italic>a</italic>, <italic>a</italic>′) represents the contact rate between persons of age <italic>a</italic>′ and sex <italic>j</italic>, and those of age <italic>a</italic> and sex <italic>i</italic> [<xref ref-type="bibr" rid="pcbi.1005719.ref032">32</xref>, <xref ref-type="bibr" rid="pcbi.1005719.ref033">33</xref>], <italic>β</italic><sub>1</sub> and <italic>β</italic><sub>2</sub> are proportionality parameters determining the transmissibility of primary infection and reactivation/re-infection, and <italic>M</italic> is the maximum age. As the data do not extend beyond 80 years we take <italic>M</italic> = 80 years. Notice that λ<sup><italic>j</italic></sup>(<italic>a</italic>)<italic>S</italic><sup><italic>j</italic></sup>(<italic>a</italic>) and (<italic>ρ</italic><sup><italic>j</italic></sup>(<italic>a</italic>) + <italic>z</italic> λ<sup><italic>j</italic></sup>(<italic>a</italic>))<italic>L</italic><sup><italic>j</italic></sup>(<italic>a</italic>) are the incidence of primary infection and the incidence of reactivation and re-infection, so that <italic>β</italic><sub>1</sub>λ<sup><italic>j</italic></sup>(<italic>a</italic>)<italic>S</italic><sup><italic>j</italic></sup>(<italic>a</italic>) and <italic>β</italic><sub>2</sub>(<italic>ρ</italic><sup><italic>j</italic></sup>(<italic>a</italic>) + <italic>z</italic> λ<sup><italic>j</italic></sup>(<italic>a</italic>))<italic>L</italic><sup><italic>j</italic></sup>(<italic>a</italic>) are the infectious output generated by primary infection and reactivation/re-infection, respectively [<xref ref-type="bibr" rid="pcbi.1005719.ref030">30</xref>].</p>
<p>As in earlier studies, contact rates are hard-wired into the model using data on social contact patterns, thereby adopting the social contact hypothesis [<xref ref-type="bibr" rid="pcbi.1005719.ref032">32</xref>–<xref ref-type="bibr" rid="pcbi.1005719.ref034">34</xref>]. Here we use the mixing matrix based on reported physical contacts [<xref ref-type="bibr" rid="pcbi.1005719.ref032">32</xref>]. The discretized contact function and demographic data are available at github.com/mvboven/cmv-serology.</p>
<p>Below, we consider a suite of simplifications and variations of the full model specified by Eqs <xref ref-type="disp-formula" rid="pcbi.1005719.e003">(1)</xref> and <xref ref-type="disp-formula" rid="pcbi.1005719.e004">(2)</xref>. In the simplifications, we assume that (i) there is no re-infection (<italic>z</italic> = 0), (ii) there is no reactivation (<italic>ρ</italic><sup><italic>i</italic></sup>(0) = 0), or (iii) reactivation and re-infection are not infectious (<italic>β</italic><sub>2</sub> = 0). We also consider a variation of the model in which re-infection and reactivation do not only occur upon transition from <italic>L</italic> to <italic>B</italic>, but also in the <italic>B</italic> compartment. In these models the infectious output generated by reactivation and re-infection in <xref ref-type="disp-formula" rid="pcbi.1005719.e004">Eq (2)</xref> (<italic>β</italic><sub>2</sub>(<italic>ρ</italic><sup><italic>j</italic></sup>(<italic>a</italic>′) + <italic>zλ</italic><sup><italic>j</italic></sup>(<italic>a</italic>′))<italic>L</italic><sup><italic>j</italic></sup>(<italic>a</italic>′)) is replaced by <italic>β</italic><sub>2</sub>(<italic>ρ</italic><sup><italic>j</italic></sup>(<italic>a</italic>′) + <italic>zλ</italic><sup><italic>j</italic></sup>(<italic>a</italic>′))(<italic>L</italic><sup><italic>j</italic></sup>(<italic>a</italic>′) + <italic>B</italic><sup><italic>j</italic></sup>(<italic>a</italic>′)).</p>
</sec>
<sec id="sec008">
<title>Solution and discretization</title>
<p>The differential equations can be solved in terms of the forces of infection using the variation of constants method. Here we assume, based on results of the mixture model, that a non-negligible fraction of infants is infected in the first six months of life and the fraction infected is equal in female and male infants [<xref ref-type="bibr" rid="pcbi.1005719.ref021">21</xref>]. Hence, we have <italic>S</italic><sup>♀</sup>(0) = <italic>S</italic><sup>♂</sup>(0) = <italic>S</italic><sub>0</sub>, <italic>L</italic><sup>♂</sup>(0) = <italic>L</italic><sup>♀</sup>(0) = 1 − <italic>S</italic><sub>0</sub>, and <italic>B</italic><sup>♀</sup>(0) = <italic>B</italic><sup>♂</sup>(0) = 0 as initial conditions, and the solution of <xref ref-type="disp-formula" rid="pcbi.1005719.e003">(1)</xref> is given by
<disp-formula id="pcbi.1005719.e006"><alternatives><graphic id="pcbi.1005719.e006g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005719.e006" xlink:type="simple"/><mml:math display="block" id="M6"><mml:mtable columnalign="left"><mml:mtr columnalign="left"><mml:mtd columnalign="left"><mml:mrow><mml:msup><mml:mi>S</mml:mi> <mml:mi>i</mml:mi></mml:msup> <mml:mrow><mml:mo>(</mml:mo> <mml:mi>a</mml:mi> <mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mtd> <mml:mtd columnalign="left"><mml:mrow><mml:mo>=</mml:mo> <mml:msubsup><mml:mi>S</mml:mi> <mml:mn>0</mml:mn> <mml:mi>i</mml:mi></mml:msubsup> <mml:mspace width="1pt"/><mml:msup><mml:mi>e</mml:mi> <mml:mrow><mml:mo>−</mml:mo> <mml:msubsup><mml:mo>∫</mml:mo> <mml:mn>0</mml:mn> <mml:mi>a</mml:mi></mml:msubsup> <mml:mo>λ</mml:mo> <mml:mrow><mml:mo>(</mml:mo> <mml:mi>τ</mml:mi> <mml:mo>)</mml:mo></mml:mrow> <mml:mi>d</mml:mi> <mml:mi>τ</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mtd></mml:mtr> <mml:mtr columnalign="left"><mml:mtd columnalign="left"><mml:mrow><mml:msup><mml:mi>L</mml:mi> <mml:mi>i</mml:mi></mml:msup> <mml:mrow><mml:mo>(</mml:mo> <mml:mi>a</mml:mi> <mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mtd> <mml:mtd columnalign="left"><mml:mrow><mml:mo>=</mml:mo> <mml:mrow><mml:mo>(</mml:mo> <mml:mrow><mml:mn>1</mml:mn> <mml:mo>−</mml:mo> <mml:msubsup><mml:mi>S</mml:mi> <mml:mn>0</mml:mn> <mml:mi>i</mml:mi></mml:msubsup></mml:mrow> <mml:mo>)</mml:mo></mml:mrow> <mml:mspace width="1pt"/><mml:msup><mml:mi>e</mml:mi> <mml:mrow><mml:mo>−</mml:mo> <mml:msubsup><mml:mo>∫</mml:mo> <mml:mn>0</mml:mn> <mml:mi>a</mml:mi></mml:msubsup> <mml:mi>ρ</mml:mi> <mml:mrow><mml:mo>(</mml:mo> <mml:mi>τ</mml:mi> <mml:mo>)</mml:mo></mml:mrow> <mml:mo>+</mml:mo> <mml:mi>z</mml:mi> <mml:mo>λ</mml:mo> <mml:mrow><mml:mo>(</mml:mo> <mml:mi>τ</mml:mi> <mml:mo>)</mml:mo></mml:mrow> <mml:mi>d</mml:mi> <mml:mi>τ</mml:mi></mml:mrow></mml:msup> <mml:mo>+</mml:mo> <mml:msubsup><mml:mi>S</mml:mi> <mml:mn>0</mml:mn> <mml:mi>i</mml:mi></mml:msubsup> <mml:mspace width="1pt"/><mml:msubsup><mml:mo>∫</mml:mo> <mml:mn>0</mml:mn> <mml:mi>a</mml:mi></mml:msubsup> <mml:mo>λ</mml:mo> <mml:mrow><mml:mo>(</mml:mo> <mml:mi>τ</mml:mi> <mml:mo>)</mml:mo></mml:mrow> <mml:msup><mml:mi>e</mml:mi> <mml:mrow><mml:mo>−</mml:mo> <mml:msubsup><mml:mo>∫</mml:mo> <mml:mn>0</mml:mn> <mml:mi>τ</mml:mi></mml:msubsup> <mml:mo>λ</mml:mo> <mml:mrow><mml:mo>(</mml:mo> <mml:msup><mml:mi>τ</mml:mi> <mml:mo>′</mml:mo></mml:msup> <mml:mo>)</mml:mo></mml:mrow> <mml:mi>d</mml:mi> <mml:msup><mml:mi>τ</mml:mi> <mml:mo>′</mml:mo></mml:msup> <mml:mo>−</mml:mo> <mml:msubsup><mml:mo>∫</mml:mo> <mml:mi>τ</mml:mi> <mml:mi>a</mml:mi></mml:msubsup> <mml:mi>ρ</mml:mi> <mml:mrow><mml:mo>(</mml:mo> <mml:msup><mml:mi>τ</mml:mi> <mml:mo>′</mml:mo></mml:msup> <mml:mo>)</mml:mo></mml:mrow> <mml:mo>+</mml:mo> <mml:mi>z</mml:mi> <mml:mo>λ</mml:mo> <mml:mrow><mml:mo>(</mml:mo> <mml:msup><mml:mi>τ</mml:mi> <mml:mo>′</mml:mo></mml:msup> <mml:mo>)</mml:mo></mml:mrow> <mml:mi>d</mml:mi> <mml:msup><mml:mi>τ</mml:mi> <mml:mo>′</mml:mo></mml:msup></mml:mrow></mml:msup> <mml:mi>d</mml:mi> <mml:mi>τ</mml:mi> <mml:mspace width="1pt"/><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives> <label>(3)</label></disp-formula>
Insertion of <xref ref-type="disp-formula" rid="pcbi.1005719.e006">Eq (3)</xref> in <xref ref-type="disp-formula" rid="pcbi.1005719.e004">Eq (2)</xref> yields two integral equations for the age-specific forces of infection in females and males [<xref ref-type="bibr" rid="pcbi.1005719.ref034">34</xref>–<xref ref-type="bibr" rid="pcbi.1005719.ref037">37</xref>]. These equations cannot be solved explicitly in general. It is possible, however, to solve the equations for specific functions.</p>
<p>Here, we assume that reactivation and contact rates are constant on certain predefined age-intervals. From <xref ref-type="disp-formula" rid="pcbi.1005719.e004">Eq (2)</xref>, it then follows that the force of infection is piecewise constant as well. Throughout, we consider age intervals of fixed size Δ<italic>a</italic> = 5 years, so that the limits of the <italic>n</italic> = <italic>M</italic>/Δ<italic>a</italic> = 16 age classes are defined by the vector <bold>a</bold> = (0, Δ <italic>a</italic>, 2Δ <italic>a</italic>, …, <italic>n</italic>Δ <italic>a</italic>). Hence, the <italic>j</italic>-th class (<italic>j</italic> = 1, …, <italic>n</italic>) contains all persons with age in the interval [<italic>a</italic><sub>[<italic>j</italic>]</sub>, <italic>a</italic><sub>[<italic>j</italic> + 1]</sub>), where <italic>a</italic><sub>[<italic>j</italic>]</sub> denotes the <italic>j</italic>-th element of <bold>a</bold>. Subsequently, the forces of infection λ<sup><italic>i</italic></sup>(<italic>a</italic>) and reactivation rates <italic>ρ</italic><sup><italic>i</italic></sup>(<italic>a</italic>) are replaced by their counterparts <inline-formula id="pcbi.1005719.e007"><alternatives><graphic id="pcbi.1005719.e007g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005719.e007" xlink:type="simple"/><mml:math display="inline" id="M7"><mml:msubsup><mml:mo>λ</mml:mo> <mml:mi>j</mml:mi> <mml:mi>i</mml:mi></mml:msubsup></mml:math></alternatives></inline-formula> and <inline-formula id="pcbi.1005719.e008"><alternatives><graphic id="pcbi.1005719.e008g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005719.e008" xlink:type="simple"/><mml:math display="inline" id="M8"><mml:msubsup><mml:mi>ρ</mml:mi> <mml:mi>j</mml:mi> <mml:mi>i</mml:mi></mml:msubsup></mml:math></alternatives></inline-formula>. Similarly, <italic>S</italic><sup><italic>i</italic></sup>(<italic>a</italic>), <italic>L</italic><sup><italic>i</italic></sup>(<italic>a</italic>), and <italic>B</italic><sup><italic>i</italic></sup>(<italic>a</italic>) at the borders of the age-intervals are given by <inline-formula id="pcbi.1005719.e009"><alternatives><graphic id="pcbi.1005719.e009g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005719.e009" xlink:type="simple"/><mml:math display="inline" id="M9"><mml:msubsup><mml:mi>S</mml:mi> <mml:mi>j</mml:mi> <mml:mi>i</mml:mi></mml:msubsup></mml:math></alternatives></inline-formula>, <inline-formula id="pcbi.1005719.e010"><alternatives><graphic id="pcbi.1005719.e010g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005719.e010" xlink:type="simple"/><mml:math display="inline" id="M10"><mml:msubsup><mml:mi>L</mml:mi> <mml:mi>j</mml:mi> <mml:mi>i</mml:mi></mml:msubsup></mml:math></alternatives></inline-formula>, and <inline-formula id="pcbi.1005719.e011"><alternatives><graphic id="pcbi.1005719.e011g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005719.e011" xlink:type="simple"/><mml:math display="inline" id="M11"><mml:msubsup><mml:mi>B</mml:mi> <mml:mi>j</mml:mi> <mml:mi>i</mml:mi></mml:msubsup></mml:math></alternatives></inline-formula>. Insertion in <xref ref-type="disp-formula" rid="pcbi.1005719.e006">Eq (3)</xref> and integrating over the (constant) rates yields
<disp-formula id="pcbi.1005719.e012"><alternatives><graphic id="pcbi.1005719.e012g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005719.e012" xlink:type="simple"/><mml:math display="block" id="M12"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msubsup><mml:mi>S</mml:mi> <mml:mi>j</mml:mi> <mml:mi>i</mml:mi></mml:msubsup> <mml:mo>=</mml:mo></mml:mrow></mml:mtd> <mml:mtd columnalign="left"><mml:mrow><mml:msub><mml:mi>S</mml:mi> <mml:mn>0</mml:mn></mml:msub> <mml:mspace width="3.33333pt"/><mml:msup><mml:mi>e</mml:mi> <mml:mrow><mml:mo>-</mml:mo> <mml:mo>Δ</mml:mo> <mml:mi>a</mml:mi> <mml:msubsup><mml:mo>∑</mml:mo> <mml:mrow><mml:mi>k</mml:mi> <mml:mo>=</mml:mo> <mml:mn>1</mml:mn></mml:mrow> <mml:mi>j</mml:mi></mml:msubsup> <mml:msubsup><mml:mo>λ</mml:mo> <mml:mi>k</mml:mi> <mml:mi>i</mml:mi></mml:msubsup></mml:mrow></mml:msup></mml:mrow></mml:mtd></mml:mtr> <mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msubsup><mml:mi>L</mml:mi> <mml:mi>j</mml:mi> <mml:mi>i</mml:mi></mml:msubsup> <mml:mo>=</mml:mo></mml:mrow></mml:mtd> <mml:mtd columnalign="left"><mml:mrow><mml:mo>(</mml:mo> <mml:mn>1</mml:mn> <mml:mo>-</mml:mo> <mml:msub><mml:mi>S</mml:mi> <mml:mn>0</mml:mn></mml:msub> <mml:mo>)</mml:mo> <mml:mspace width="3.33333pt"/><mml:msup><mml:mi>e</mml:mi> <mml:mrow><mml:mo>-</mml:mo> <mml:mo>Δ</mml:mo> <mml:mi>a</mml:mi> <mml:msubsup><mml:mo>∑</mml:mo> <mml:mrow><mml:mi>k</mml:mi> <mml:mo>=</mml:mo> <mml:mn>1</mml:mn></mml:mrow> <mml:mi>j</mml:mi></mml:msubsup> <mml:msubsup><mml:mi>ρ</mml:mi> <mml:mi>k</mml:mi> <mml:mi>i</mml:mi></mml:msubsup> <mml:mo>+</mml:mo> <mml:mi>z</mml:mi> <mml:msubsup><mml:mo>λ</mml:mo> <mml:mi>k</mml:mi> <mml:mi>i</mml:mi></mml:msubsup></mml:mrow></mml:msup> <mml:mspace width="3.33333pt"/><mml:mo>+</mml:mo></mml:mrow></mml:mtd></mml:mtr> <mml:mtr><mml:mtd/><mml:mtd columnalign="left"><mml:mrow><mml:msub><mml:mi>S</mml:mi> <mml:mn>0</mml:mn></mml:msub> <mml:mspace width="3.33333pt"/><mml:munderover><mml:mo>∑</mml:mo> <mml:mrow><mml:mi>k</mml:mi> <mml:mo>=</mml:mo> <mml:mn>1</mml:mn></mml:mrow> <mml:mi>j</mml:mi></mml:munderover> <mml:mspace width="3.33333pt"/><mml:msubsup><mml:mo>λ</mml:mo> <mml:mi>k</mml:mi> <mml:mi>i</mml:mi></mml:msubsup> <mml:mfrac><mml:mrow><mml:msup><mml:mi>e</mml:mi> <mml:mrow><mml:mo>-</mml:mo> <mml:mo>Δ</mml:mo> <mml:mi>a</mml:mi> <mml:mo>(</mml:mo> <mml:msubsup><mml:mi>ρ</mml:mi> <mml:mi>k</mml:mi> <mml:mi>i</mml:mi></mml:msubsup> <mml:mo>+</mml:mo> <mml:mi>z</mml:mi> <mml:msubsup><mml:mo>λ</mml:mo> <mml:mi>k</mml:mi> <mml:mi>i</mml:mi></mml:msubsup> <mml:mo>)</mml:mo></mml:mrow></mml:msup> <mml:mo>-</mml:mo> <mml:msup><mml:mi>e</mml:mi> <mml:mrow><mml:mo>-</mml:mo> <mml:mo>Δ</mml:mo> <mml:mi>a</mml:mi> <mml:msubsup><mml:mo>λ</mml:mo> <mml:mi>k</mml:mi> <mml:mi>i</mml:mi></mml:msubsup></mml:mrow></mml:msup></mml:mrow> <mml:mrow><mml:mo>(</mml:mo> <mml:mn>1</mml:mn> <mml:mo>-</mml:mo> <mml:mi>z</mml:mi> <mml:mo>)</mml:mo> <mml:msubsup><mml:mo>λ</mml:mo> <mml:mi>k</mml:mi> <mml:mi>i</mml:mi></mml:msubsup> <mml:mo>-</mml:mo> <mml:msubsup><mml:mi>ρ</mml:mi> <mml:mi>k</mml:mi> <mml:mi>i</mml:mi></mml:msubsup></mml:mrow></mml:mfrac> <mml:msup><mml:mi>e</mml:mi> <mml:mrow><mml:mo>-</mml:mo> <mml:mo>Δ</mml:mo> <mml:mi>a</mml:mi> <mml:mo>(</mml:mo> <mml:msubsup><mml:mo>∑</mml:mo> <mml:mrow><mml:mi>ℓ</mml:mi> <mml:mo>=</mml:mo> <mml:mn>1</mml:mn></mml:mrow> <mml:mrow><mml:mi>k</mml:mi> <mml:mo>-</mml:mo> <mml:mn>1</mml:mn></mml:mrow></mml:msubsup> <mml:msubsup><mml:mo>λ</mml:mo> <mml:mi>ℓ</mml:mi> <mml:mi>i</mml:mi></mml:msubsup> <mml:mo>-</mml:mo> <mml:msubsup><mml:mo>∑</mml:mo> <mml:mrow><mml:mi>ℓ</mml:mi> <mml:mo>=</mml:mo> <mml:mi>k</mml:mi> <mml:mo>+</mml:mo> <mml:mn>1</mml:mn></mml:mrow> <mml:mi>j</mml:mi></mml:msubsup> <mml:msubsup><mml:mi>ρ</mml:mi> <mml:mi>ℓ</mml:mi> <mml:mi>i</mml:mi></mml:msubsup> <mml:mo>+</mml:mo> <mml:mi>z</mml:mi> <mml:msubsup><mml:mo>λ</mml:mo> <mml:mi>ℓ</mml:mi> <mml:mi>i</mml:mi></mml:msubsup> <mml:mo>)</mml:mo></mml:mrow></mml:msup> <mml:mspace width="3.33333pt"/><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives> <label>(4)</label></disp-formula>
where <italic>i</italic> ∈ {♀, ♂} and <inline-formula id="pcbi.1005719.e013"><alternatives><graphic id="pcbi.1005719.e013g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005719.e013" xlink:type="simple"/><mml:math display="inline" id="M13"><mml:mrow><mml:msubsup><mml:mi>B</mml:mi> <mml:mi>j</mml:mi> <mml:mi>i</mml:mi></mml:msubsup> <mml:mo>=</mml:mo> <mml:mn>1</mml:mn> <mml:mo>-</mml:mo> <mml:msubsup><mml:mi>S</mml:mi> <mml:mi>j</mml:mi> <mml:mi>i</mml:mi></mml:msubsup> <mml:mo>-</mml:mo> <mml:msubsup><mml:mi>L</mml:mi> <mml:mi>j</mml:mi> <mml:mi>i</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>. Insertion of <xref ref-type="disp-formula" rid="pcbi.1005719.e012">Eq (4)</xref> in <xref ref-type="disp-formula" rid="pcbi.1005719.e004">Eq (2)</xref> and making use of the fact that the cumulative incidences of infection and reactivation/re-infection in age class <italic>j</italic> are given by <inline-formula id="pcbi.1005719.e014"><alternatives><graphic id="pcbi.1005719.e014g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005719.e014" xlink:type="simple"/><mml:math display="inline" id="M14"><mml:mrow><mml:msubsup><mml:mo>∫</mml:mo> <mml:mrow><mml:msub><mml:mi>a</mml:mi> <mml:mrow><mml:mo>[</mml:mo> <mml:mi>j</mml:mi> <mml:mo>]</mml:mo></mml:mrow></mml:msub></mml:mrow> <mml:msub><mml:mi>a</mml:mi> <mml:mrow><mml:mo>[</mml:mo> <mml:mi>j</mml:mi> <mml:mo>+</mml:mo> <mml:mn>1</mml:mn> <mml:mo>]</mml:mo></mml:mrow></mml:msub></mml:msubsup> <mml:msup><mml:mo>λ</mml:mo> <mml:mi>i</mml:mi></mml:msup> <mml:mrow><mml:mo>(</mml:mo> <mml:mi>a</mml:mi> <mml:mo>)</mml:mo></mml:mrow> <mml:msup><mml:mi>S</mml:mi> <mml:mi>i</mml:mi></mml:msup> <mml:mrow><mml:mo>(</mml:mo> <mml:mi>a</mml:mi> <mml:mo>)</mml:mo></mml:mrow> <mml:mi>d</mml:mi> <mml:mi>a</mml:mi> <mml:mo>=</mml:mo> <mml:msup><mml:mi>S</mml:mi> <mml:mi>i</mml:mi></mml:msup> <mml:mrow><mml:mo>(</mml:mo> <mml:msub><mml:mi>a</mml:mi> <mml:mrow><mml:mo>[</mml:mo> <mml:mi>j</mml:mi> <mml:mo>]</mml:mo></mml:mrow></mml:msub> <mml:mo>)</mml:mo></mml:mrow> <mml:mo>-</mml:mo> <mml:msup><mml:mi>S</mml:mi> <mml:mi>i</mml:mi></mml:msup> <mml:mrow><mml:mo>(</mml:mo> <mml:msub><mml:mi>a</mml:mi> <mml:mrow><mml:mo>[</mml:mo> <mml:mi>j</mml:mi> <mml:mo>+</mml:mo> <mml:mn>1</mml:mn> <mml:mo>]</mml:mo></mml:mrow></mml:msub> <mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula> and <italic>B</italic><sup><italic>i</italic></sup>(<italic>a</italic><sub>[<italic>j</italic> + 1]</sub>) − <italic>B</italic><sup><italic>i</italic></sup>(<italic>a</italic><sub>[<italic>j</italic>]</sub>), yields 32 equations (16 per sex) for the 32 forces of infection.</p>
</sec>
<sec id="sec009">
<title>Estimation and model selection</title>
<p>As in the mixture model with spline mixing parameters, the log-likelihood of each observation is given by a mixture distribution, where the spline functions are replaced by <italic>S</italic><sup><italic>i</italic></sup>(<italic>a</italic>), <italic>L</italic><sup><italic>i</italic></sup>(<italic>a</italic>), and <italic>B</italic><sup><italic>i</italic></sup>(<italic>a</italic>). For instance, the likelihood contribution of a sample with antibody measurement <italic>c</italic> in a person of sex <italic>i</italic> and age <italic>a</italic> is given by
<disp-formula id="pcbi.1005719.e015"><alternatives><graphic id="pcbi.1005719.e015g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005719.e015" xlink:type="simple"/><mml:math display="block" id="M15"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msup><mml:mi>S</mml:mi> <mml:mi>i</mml:mi></mml:msup> <mml:mrow><mml:mo>(</mml:mo> <mml:mi>a</mml:mi> <mml:mo>)</mml:mo></mml:mrow> <mml:msub><mml:mi>f</mml:mi> <mml:mi>S</mml:mi></mml:msub> <mml:mrow><mml:mo>(</mml:mo> <mml:mi>c</mml:mi> <mml:mo>)</mml:mo></mml:mrow> <mml:mo>+</mml:mo> <mml:msup><mml:mi>L</mml:mi> <mml:mi>i</mml:mi></mml:msup> <mml:mrow><mml:mo>(</mml:mo> <mml:mi>a</mml:mi> <mml:mo>)</mml:mo></mml:mrow> <mml:msub><mml:mi>f</mml:mi> <mml:mi>L</mml:mi></mml:msub> <mml:mrow><mml:mo>(</mml:mo> <mml:mi>c</mml:mi> <mml:mo>)</mml:mo></mml:mrow> <mml:mo>+</mml:mo> <mml:msup><mml:mi>B</mml:mi> <mml:mi>i</mml:mi></mml:msup> <mml:mrow><mml:mo>(</mml:mo> <mml:mi>a</mml:mi> <mml:mo>)</mml:mo></mml:mrow> <mml:msub><mml:mi>f</mml:mi> <mml:mi>B</mml:mi></mml:msub> <mml:mrow><mml:mo>(</mml:mo> <mml:mi>c</mml:mi> <mml:mo>)</mml:mo></mml:mrow> <mml:mspace width="3.33333pt"/><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives></disp-formula>
where <italic>S</italic><sup><italic>i</italic></sup>(<italic>a</italic>), <italic>L</italic><sup><italic>i</italic></sup>(<italic>a</italic>), and <italic>B</italic><sup><italic>i</italic></sup>(<italic>a</italic>) are the age specific prevalences in sex <italic>i</italic>, and <italic>f</italic><sub><italic>S</italic></sub>(<italic>c</italic>), <italic>f</italic><sub><italic>L</italic></sub>(<italic>c</italic>), and <italic>f</italic><sub><italic>B</italic></sub>(<italic>c</italic>) are the densities of the mixture distributions at antibody concentration <italic>c</italic>.</p>
<p>In both sexes, reactivation rates are modeled by piecewise constant functions with steps at 20 and 50 years, i.e. with rates that are constant on the intervals [0, 20), [20, 50), and [50, 80) years. Hence, the reactivation rates are characterized by three parameters in each sex, viz. <inline-formula id="pcbi.1005719.e016"><alternatives><graphic id="pcbi.1005719.e016g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005719.e016" xlink:type="simple"/><mml:math display="inline" id="M16"><mml:msubsup><mml:mi>ρ</mml:mi> <mml:mrow><mml:mo>[</mml:mo> <mml:mn>0</mml:mn> <mml:mo>,</mml:mo> <mml:mn>20</mml:mn> <mml:mo>)</mml:mo></mml:mrow> <mml:mi>i</mml:mi></mml:msubsup></mml:math></alternatives></inline-formula>, <inline-formula id="pcbi.1005719.e017"><alternatives><graphic id="pcbi.1005719.e017g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005719.e017" xlink:type="simple"/><mml:math display="inline" id="M17"><mml:msubsup><mml:mi>ρ</mml:mi> <mml:mrow><mml:mo>[</mml:mo> <mml:mn>20</mml:mn> <mml:mo>,</mml:mo> <mml:mn>50</mml:mn> <mml:mo>)</mml:mo></mml:mrow> <mml:mi>i</mml:mi></mml:msubsup></mml:math></alternatives></inline-formula>, and <inline-formula id="pcbi.1005719.e018"><alternatives><graphic id="pcbi.1005719.e018g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005719.e018" xlink:type="simple"/><mml:math display="inline" id="M18"><mml:mrow><mml:msubsup><mml:mi>ρ</mml:mi> <mml:mrow><mml:mrow><mml:mo>[</mml:mo> <mml:mrow><mml:mn>50</mml:mn> <mml:mo>,</mml:mo> <mml:mn>80</mml:mn></mml:mrow> <mml:mo>)</mml:mo></mml:mrow></mml:mrow> <mml:mi>i</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> (<italic>i</italic> ∈ {♀, ♂}).</p>
<p>Bayesian parameter estimates are obtained using Markov chain Monte Carlo (MCMC). Initially, results were obtained using tailored Mathematica code, using a single-component random walk metropolis algorithm while solving the consistency equations for the forces of infection using a Quasi-Newton (secant) method. As this became exceedingly slow for specific models, we recoded the models using Hamiltonian Monte Carlo with Stan (mc-stan.org). Here, the discretized equations for the forces of infection <xref ref-type="disp-formula" rid="pcbi.1005719.e004">(2)</xref> are solved by specifying that the differences between the left- and right-hand sides are small, and approximately <inline-formula id="pcbi.1005719.e019"><alternatives><graphic id="pcbi.1005719.e019g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005719.e019" xlink:type="simple"/><mml:math display="inline" id="M19"><mml:mrow><mml:mi mathvariant="script">N</mml:mi> <mml:mo>(</mml:mo> <mml:mn>0</mml:mn> <mml:mo>,</mml:mo> <mml:msup><mml:mn>10</mml:mn> <mml:mrow><mml:mo>-</mml:mo> <mml:mn>4</mml:mn></mml:mrow></mml:msup> <mml:mo>)</mml:mo></mml:mrow></mml:math></alternatives></inline-formula> (mean and scale) distributed. Cross-checking of the two methods yielded very similar results. All programs are available at github.com/mvboven/cmv-serology.</p>
<p>Prior distributions of the parameters are as follows: <inline-formula id="pcbi.1005719.e020"><alternatives><graphic id="pcbi.1005719.e020g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005719.e020" xlink:type="simple"/><mml:math display="inline" id="M20"><mml:mrow><mml:msub><mml:mi>β</mml:mi> <mml:mn>1</mml:mn></mml:msub> <mml:mo>∼</mml:mo> <mml:mi mathvariant="script">N</mml:mi> <mml:mrow><mml:mo>(</mml:mo> <mml:mn>0</mml:mn> <mml:mo>.</mml:mo> <mml:mn>1</mml:mn> <mml:mo>,</mml:mo> <mml:mn>10</mml:mn> <mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula> (mean and scale), <inline-formula id="pcbi.1005719.e021"><alternatives><graphic id="pcbi.1005719.e021g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005719.e021" xlink:type="simple"/><mml:math display="inline" id="M21"><mml:mrow><mml:msub><mml:mi>β</mml:mi> <mml:mn>2</mml:mn></mml:msub> <mml:mo>∼</mml:mo> <mml:mi mathvariant="script">N</mml:mi> <mml:mrow><mml:mo>(</mml:mo> <mml:mn>0</mml:mn> <mml:mo>.</mml:mo> <mml:mn>1</mml:mn> <mml:mo>,</mml:mo> <mml:mn>10</mml:mn> <mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula>, <inline-formula id="pcbi.1005719.e022"><alternatives><graphic id="pcbi.1005719.e022g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005719.e022" xlink:type="simple"/><mml:math display="inline" id="M22"><mml:mrow><mml:mi>z</mml:mi> <mml:mo>∼</mml:mo> <mml:mi mathvariant="script">U</mml:mi> <mml:mo>(</mml:mo> <mml:mn>0</mml:mn> <mml:mo>,</mml:mo> <mml:mn>1</mml:mn> <mml:mo>)</mml:mo></mml:mrow></mml:math></alternatives></inline-formula>, <inline-formula id="pcbi.1005719.e023"><alternatives><graphic id="pcbi.1005719.e023g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005719.e023" xlink:type="simple"/><mml:math display="inline" id="M23"><mml:mrow><mml:msub><mml:mi>μ</mml:mi> <mml:mi>ρ</mml:mi></mml:msub> <mml:mo>∼</mml:mo> <mml:mi mathvariant="script">N</mml:mi> <mml:mrow><mml:mo>(</mml:mo> <mml:mn>0</mml:mn> <mml:mo>,</mml:mo> <mml:mn>10</mml:mn> <mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula>, <inline-formula id="pcbi.1005719.e024"><alternatives><graphic id="pcbi.1005719.e024g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005719.e024" xlink:type="simple"/><mml:math display="inline" id="M24"><mml:mrow><mml:mn>1</mml:mn> <mml:mo>/</mml:mo> <mml:msub><mml:mi>σ</mml:mi> <mml:mi>ρ</mml:mi></mml:msub> <mml:mo>∼</mml:mo> <mml:mi mathvariant="script">N</mml:mi> <mml:mrow><mml:mo>(</mml:mo> <mml:mn>0</mml:mn> <mml:mo>,</mml:mo> <mml:mn>10</mml:mn> <mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula>, and <inline-formula id="pcbi.1005719.e025"><alternatives><graphic id="pcbi.1005719.e025g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005719.e025" xlink:type="simple"/><mml:math display="inline" id="M25"><mml:mrow><mml:msubsup><mml:mi>ρ</mml:mi> <mml:mi>x</mml:mi> <mml:mi>i</mml:mi></mml:msubsup> <mml:mo>∼</mml:mo> <mml:mi mathvariant="script">N</mml:mi> <mml:mrow><mml:mo>(</mml:mo> <mml:msub><mml:mi>μ</mml:mi> <mml:mi>ρ</mml:mi></mml:msub> <mml:mo>,</mml:mo> <mml:msub><mml:mi>σ</mml:mi> <mml:mi>ρ</mml:mi></mml:msub> <mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula> for all <italic>i</italic> and <italic>x</italic>. Whenever applicable, distributions are truncated to be positive. With these prior parameter distributions, the joint posterior distribution is strongly dominated by the data. Ten chains of 3,000 iterations are run in parallel, of which the first 500 iterations (warmup) are discarded. We apply 1/5 thinning, yielding a total of 5,000 samples per model scenario. For all parameters, effective sample sizes usually lie between 3,000 and 4,500. Convergence of chains is assessed visually, and by assessment of the empirical variance within and between chains [<xref ref-type="bibr" rid="pcbi.1005719.ref038">38</xref>]. To prevent the occurrence of divergent transitions we set <sc>ADAPT</sc>_<sc>DELTA</sc> = 0.99. Parameter estimates and bounds of credible intervals are represented by 2.5, 50, and 97.5 percentiles of the posterior samples. Results are usually obtained in 1-3 hours on a personal computer.</p>
<p>Model selection is based on WAIC, a measure for predictive performance, and WBIC, a measure for identifying the most likely model generating the data [<xref ref-type="bibr" rid="pcbi.1005719.ref039">39</xref>–<xref ref-type="bibr" rid="pcbi.1005719.ref041">41</xref>]. WAIC is obtained directly from the posterior likelihood using the R-package <sc>loo</sc> (cran.r-project.org). WBIC is calculated in a separate run as the average log likelihood over the posterior samples, using a sampling ‘temperature’ determined by the number of observations [<xref ref-type="bibr" rid="pcbi.1005719.ref039">39</xref>].</p>
</sec>
</sec>
<sec id="sec010" sec-type="results">
<title>Results</title>
<sec id="sec011">
<title>Classification</title>
<p>
<xref ref-type="fig" rid="pcbi.1005719.g001">Fig 1</xref> presents the data stratified by sex and age, with fit of the statistical model. The data and model fit show peaks at low antibody measurements (-2.9 U/ml and ≈-2 U/ml), corresponding to uninfected persons (denoted by S). In both sexes, there is a third peak at higher measurements (1-3 U/ml) that shifts to higher values with increasing age. This peak is composed of persons who are infected (denoted by L) and persons who are infected with high antibody concentrations (denoted by B). Overall, the model appears to describe the data well.</p>
<p>This is confirmed in <xref ref-type="fig" rid="pcbi.1005719.g003">Fig 3</xref>, which shows the estimated components of the mixture distribution and diagnostic characteristics of the classification. The component distribution of uninfected persons hardly overlaps with the two component distributions for infected persons, while there is some overlap between the distributions of infected persons. This can be made more precise using detection theory. Specifically, in <xref ref-type="fig" rid="pcbi.1005719.g003">Fig 3</xref> we graph the specificity <italic>Sp</italic> (the probability of correctly classifying a negative subject) and sensitivity <italic>Se</italic> (the probability of correctly classifying a positive subject) in a receiver operating characteristic (ROC) graph with antibody concentration specifying a cut-off for binary classification as parameter [<xref ref-type="bibr" rid="pcbi.1005719.ref042">42</xref>–<xref ref-type="bibr" rid="pcbi.1005719.ref044">44</xref>]. Subsequently, we use the maximal Youden index (i.e. max(<italic>Se</italic> + <italic>Sp</italic> − 1)) to choose an optimal cut-off, and find that classification of persons as uninfected versus infected is near perfect (Youden index: 0.97, at cut-off -0.70 U/ml), while classification of persons with high antibody concentrations is good (Youden index: 0.71, at cut-off 1.81 U/ml). These results show that the classification is supported by the data (i.e. has high probability yielding an informed decision).</p>
<fig id="pcbi.1005719.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1005719.g003</object-id>
<label>Fig 3</label>
<caption>
<title>Classification of samples.</title>
<p>Shown are the estimated components of the mixture distribution using the parameter posterior medians (left-hand panel; blue: susceptible; purple: infected; red: infected with increased antibody concentration), and receiver operating characteristic of binary classifications taking these estimates as ground truth (right-hand panel). The maximal Youden index for classification of uninfected versus infected persons is 0.97 at antibody concentration -0.70 U/ml, with sensitivity 0.99 and specificity 0.98. This value corresponds well with the threshold for infection of -0.8 U/ml provided by the supplier of the assay. The maximal Youden index for classification of persons with increased antibody concentration is 0.71 at antibody concentration 1.81 U/ml, with sensitivity 0.84 and specificity 0.87.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005719.g003" xlink:type="simple"/>
</fig>
<p>We further investigate whether mixture models with fewer or more components are able to provide an even better description of the data, and found that a model with two mixture components does not perform well (ΔWAIC = 300.2 in favor of the three-component mixture distribution), while performance of models with four components depends sensitively on choice of prior distribution of the fourth distribution, and often yields broad posterior antibody distributions with small estimated prevalence that overlap with the other three component distributions. Hence, a mixture model with three components gives an optimal description of the data.</p>
</sec>
<sec id="sec012">
<title>Prevalence estimation</title>
<p>
<xref ref-type="fig" rid="pcbi.1005719.g004">Fig 4</xref> shows the estimated prevalences in females and males as a function of age [<xref ref-type="bibr" rid="pcbi.1005719.ref042">42</xref>–<xref ref-type="bibr" rid="pcbi.1005719.ref044">44</xref>]. The prevalence of uninfected persons decreases gradually with age, from approximately 0.80 in infants (females: 0.81, 95%CrI: 0.77-0.85; males: 0.80, 95%CrI: 0.76-0.84) to 0.27 (95%CrI: 0.22-0.34) and 0.38 (95%CrI: 0.32-0.45) at 80 years in females and males, respectively. In both females and males the latently infected prevalence remains approximately constant, ranging from 0.15 to 0.20 in females and from 0.18 to 0.28 in males. In contrast, the prevalence of persons with increased antibodies increases strongly with age, especially in females. In fact, the prevalence of persons with increased antibodies increases from 0.09 (95%CrI: 0.06-0.13) at 20 years to 0.57 (95%CrI: 0.47-0.67) at 80 years in females, and from 0.04 (95%CrI: 0.03-0.07) to 0.37 (95%CrI: 0.28-0.46) in males. Hence, in older persons the prevalence of persons with increased antibodies is 54% (or 20 per cent points) higher in females than in males.</p>
<fig id="pcbi.1005719.g004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1005719.g004</object-id>
<label>Fig 4</label>
<caption>
<title>Estimation of age- and sex-specific prevalence.</title>
<p>Prevalence estimates are presented for females (top panel) and males (bottom panel), and for classes of low (susceptible, blue), intermediate (latently infected, purple), and high (latently infected with increased antibodies, red) antibody measurements. Shown are 1,000 samples from the posterior distribution (thin lines) with posterior medians (bold lines). Dots indicate the fraction of samples that would be classified as uninfected with the cut-off specified by the supplier of the assay. The number of samples per 1-year age group is approximately 35 (females) and 30 (males).</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005719.g004" xlink:type="simple"/>
</fig>
<p>Of particular interest is the prevalence of infection in females of childbearing age, as this group is at risk of transmission to the fetus or newborn. Using the above analyses, we find that the prevalence of infection (i.e. the combined prevalence in the L and B compartments) is 0.30 (95%CrI: 0.27-0.33) in 20-year-old females and 0.42 (95%CrI: 0.39-0.46) in 40-year-old females. If we combine these figures with the observation that approximately 20% of children are infected at six months of age, and that less than 5% of children in the Netherlands in 2007 had a mother under 20 years or over 40 years, we deduce that the probability of perinatal transmission could be between 0.20/0.42 = 0.48 and 0.20/0.30 = 0.67, with the exact figure depending on the distribution of ages at which mothers give birth. In addition, one could envisage that the highest risk of (severe) infection of the fetus or newborn is when mothers are infected or experience a reactivation episode. The estimated rates at which susceptible females of 20 and 40 years are infected are 0.0055 per year (95%CrI: 0.0036-0.0077) and 0.0092 per year (95%CrI: 0.0069-0.011) per year, respectively. The rates at which latently infected females of 20 and 40 years are re-infected or experience a reactivation episode are of similar magnitude, and are estimated at 0.0059 per year (95%CrI: 0.0038-0.0086) and 0.0093 per year (95%CrI: 0.0064-0.012), respectively. The overall rates of infection, reactivation, and re-infection in 20 and 40 year-old females are given by the sum of the above estimates, and are approximately 1% and 2% per year, respectively.</p>
</sec>
<sec id="sec013">
<title>Estimation of reactivation and re-infection rates</title>
<p>To evaluate the ability of different transmission hypotheses explaining the data, and to obtain parameter estimates that have a biological interpretation, we analyzed the data with transmission models. A comparison of model scenarios based on the information criteria WAIC and WBIC is given in <xref ref-type="table" rid="pcbi.1005719.t001">Table 1</xref>. Overall, the analyses show that models with the possibility of multiple infectious reactivations perform best (Models E and F; lowest WAIC and WBIC), that models with at most one infectious reactivation perform worse (Models A and B; ΔWAIC and ΔWBIC ≈10 − 15), and that models without reactivation or with reactivation not being infectious have very low support (Models C, D, and G). These results indicate that infectious reactivation is key to adequately explain the data with transmission models. This is true in our model with contact structure based on reported physical contacts [<xref ref-type="bibr" rid="pcbi.1005719.ref032">32</xref>], and also in an alternative model formulation that assumes a uniform contact structure (ΔWAIC = 151.9 in favor of the model with reactivation over the model without reactivation and no re-infection).</p>
<table-wrap id="pcbi.1005719.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1005719.t001</object-id>
<label>Table 1</label>
<caption>
<title>Model selection of transmission scenarios.</title>
</caption>
<alternatives>
<graphic id="pcbi.1005719.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005719.t001" xlink:type="simple"/>
<table border="0" frame="box" rules="all">
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center" style="border-top:thick">Model</th>
<th align="left" style="border-top:thick">Description</th>
<th align="center" style="border-top:thick">WAIC</th>
<th align="center" style="border-top:thick">ΔWAIC</th>
<th align="center" style="border-top:thick">WBIC</th>
<th align="center" style="border-top:thick">ΔWBIC</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center">A</td>
<td align="left">Reactivation and re-infection</td>
<td align="char" char=".">22156.2</td>
<td align="center">13.0</td>
<td align="char" char=".">22211.3</td>
<td align="center">13.7</td>
</tr>
<tr>
<td align="center">B</td>
<td align="left">No re-infection</td>
<td align="char" char=".">22155.5</td>
<td align="center">12.3</td>
<td align="char" char=".">22209.4</td>
<td align="center">11.8</td>
</tr>
<tr>
<td align="center">C</td>
<td align="left">No reactivation</td>
<td align="char" char=".">22363.6</td>
<td align="center">220.4</td>
<td align="char" char=".">22396.9</td>
<td align="center">199.3</td>
</tr>
<tr>
<td align="center">D</td>
<td align="left">Reactivation/re-infection not infectious</td>
<td align="char" char=".">22215.3</td>
<td align="center">72.1</td>
<td align="char" char=".">22247.9</td>
<td align="center">36.6</td>
</tr>
<tr>
<td align="center">E</td>
<td align="left">Multiple reactivations/re-infections</td>
<td align="char" char=".">22144.0</td>
<td align="center">0.7</td>
<td align="char" char=".">22197.6</td>
<td align="center">0</td>
</tr>
<tr>
<td align="center">F</td>
<td align="left">Multiple reactivations and no re-infection</td>
<td align="char" char=".">22143.2</td>
<td align="center">0</td>
<td align="char" char=".">22198.4</td>
<td align="center">0.8</td>
</tr>
<tr>
<td align="center">G</td>
<td align="left">Multiple re-infections and no reactivation</td>
<td align="char" char=".">22364.4</td>
<td align="center">221.2</td>
<td align="char" char=".">22396.8</td>
<td align="center">199.2</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001">
<p>For each of seven model scenarios we report the WAIC, a measure of predictive performance, and WBIC, a measure for the most likely model generating the data. Also shown are the WAIC and WBIC differences with the best fitting model. Models E-G contain the possibility of multiple reactivation/re-infection events in persons with increased antibody concentrations (the B compartment; cf. <xref ref-type="fig" rid="pcbi.1005719.g002">Fig 2</xref>).</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Within the set of models with infectious reactivation there are only small differences between models that do and do not incorporate re-infection (Model A versus Model B, and Model E versus Model F). This indicates that while infectious reactivation is essential to adequately describe the data, the analyses are inconclusive with respect to whether or not infectious re-infection should be included.</p>
<p><xref ref-type="fig" rid="pcbi.1005719.g005">Fig 5</xref> and <xref ref-type="table" rid="pcbi.1005719.t002">Table 2</xref> show parameter estimates of the model with highest statistical support (as judged by WBIC). The preferred model (Model E) includes multiple reactivations and re-infections, infectious reactivation, and infectious re-infection. In this model, the estimated transmissibility of primary infection (<italic>β</italic><sub>1</sub>) is much lower than the transmissibility of reactivation/re-infection (<italic>β</italic><sub>2</sub>). In fact, the posterior median of <italic>β</italic><sub>2</sub> is more than an order of magnitude larger than the posterior median of <italic>β</italic><sub>1</sub>. Further, the relative susceptibility to re-infection (i.e. the probability of re-infection in a contact that would lead to infection if the contacted person were uninfected) has a broad posterior distribution, and cannot be estimated with meaningful precision from the data (<inline-formula id="pcbi.1005719.e026"><alternatives><graphic id="pcbi.1005719.e026g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005719.e026" xlink:type="simple"/><mml:math display="inline" id="M26"><mml:mrow><mml:mover accent="true"><mml:mi>z</mml:mi> <mml:mo>^</mml:mo></mml:mover> <mml:mo>=</mml:mo> <mml:mn>0.32</mml:mn> <mml:mo>;</mml:mo></mml:mrow></mml:math></alternatives></inline-formula> 95%CrI: 0.017-0.84). Similar findings are obtained in other model scenarios, in particular Models A-B and E-F (<xref ref-type="table" rid="pcbi.1005719.t001">Table 1</xref>).</p>
<fig id="pcbi.1005719.g005" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1005719.g005</object-id>
<label>Fig 5</label>
<caption>
<title>Parameter estimates.</title>
<p>Shown are kernel-smoothed posterior distributions of the relative susceptibility to re-infection (<italic>z</italic>), the transmissibility of primary infection (<italic>β</italic><sub>1</sub>) and reactivation/re-infection (<italic>β</italic><sub>2</sub>), and the reactivation rates in persons aged 0-20 years (<italic>ρ</italic><sub>[0,20)</sub>, purple: females; brown: males), 20-50 years (<italic>ρ</italic><sub>[20,50)</sub>), and 50-80 years (<italic>ρ</italic><sub>[50 − 80)</sub>) of the transmission model with the possibility of multiple reactivations and re-infections (Model E in <xref ref-type="table" rid="pcbi.1005719.t001">Table 1</xref>).</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005719.g005" xlink:type="simple"/>
</fig>
<table-wrap id="pcbi.1005719.t002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1005719.t002</object-id>
<label>Table 2</label>
<caption>
<title>Parameter estimates of the transmission model.</title>
</caption>
<alternatives>
<graphic id="pcbi.1005719.t002g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005719.t002" xlink:type="simple"/>
<table border="0" frame="box" rules="all">
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="right" style="border-top:thick">Parameter</th>
<th align="left" style="border-top:thick">Description</th>
<th align="center" style="border-top:thick">Median</th>
<th align="center" style="border-top:thick">95%CrI</th>
</tr>
</thead>
<tbody>
<tr>
<td align="right"><italic>β</italic><sub>1</sub></td>
<td align="left">Transmissibility of primary infection</td>
<td align="char" char=".">0.0019</td>
<td align="center">0.000081—0.0089</td>
</tr>
<tr>
<td align="right"><italic>β</italic><sub>2</sub></td>
<td align="left">Transmissibility of re-infection/reactivation</td>
<td align="char" char=".">0.042</td>
<td align="center">0.035—0.049</td>
</tr>
<tr>
<td align="right"><italic>z</italic></td>
<td align="left">Relative susceptibility for re-infection</td>
<td align="char" char=".">0.32</td>
<td align="center">0.017—0.84</td>
</tr>
<tr>
<td align="right">
<inline-formula id="pcbi.1005719.e027">
<alternatives>
<graphic id="pcbi.1005719.e027g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005719.e027" xlink:type="simple"/>
<mml:math display="inline" id="M27">
<mml:mrow>
<mml:msubsup>
<mml:mi>ρ</mml:mi>
<mml:mrow>
<mml:mrow>
<mml:mo>[</mml:mo>
<mml:mrow>
<mml:mn>0</mml:mn>
<mml:mo>,</mml:mo>
<mml:mn>20</mml:mn>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
<mml:mo>♀</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</alternatives>
</inline-formula>
</td>
<td align="left">Reactivation rate in 0-20 year old females (<italic>yr</italic><sup>−1</sup>)</td>
<td align="char" char=".">0.013</td>
<td align="center">0.0042—0.021</td>
</tr>
<tr>
<td align="right">
<inline-formula id="pcbi.1005719.e028">
<alternatives>
<graphic id="pcbi.1005719.e028g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005719.e028" xlink:type="simple"/>
<mml:math display="inline" id="M28">
<mml:mrow>
<mml:msubsup>
<mml:mi>ρ</mml:mi>
<mml:mrow>
<mml:mrow>
<mml:mo>[</mml:mo>
<mml:mrow>
<mml:mn>20</mml:mn>
<mml:mo>,</mml:mo>
<mml:mn>50</mml:mn>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
<mml:mo>♀</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</alternatives>
</inline-formula>
</td>
<td align="left">Reactivation rate in 20-50 year old females (<italic>yr</italic><sup>−1</sup>)</td>
<td align="char" char=".">0.021</td>
<td align="center">0.013—0.029</td>
</tr>
<tr>
<td align="right">
<inline-formula id="pcbi.1005719.e029">
<alternatives>
<graphic id="pcbi.1005719.e029g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005719.e029" xlink:type="simple"/>
<mml:math display="inline" id="M29">
<mml:mrow>
<mml:msubsup>
<mml:mi>ρ</mml:mi>
<mml:mrow>
<mml:mrow>
<mml:mo>[</mml:mo>
<mml:mrow>
<mml:mn>50</mml:mn>
<mml:mo>,</mml:mo>
<mml:mn>80</mml:mn>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
<mml:mo>♀</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</alternatives>
</inline-formula>
</td>
<td align="left">Reactivation rate in 50-80 year old females (<italic>yr</italic><sup>−1</sup>)</td>
<td align="char" char=".">0.028</td>
<td align="center">0.017—0.040</td>
</tr>
<tr>
<td align="right">
<inline-formula id="pcbi.1005719.e030">
<alternatives>
<graphic id="pcbi.1005719.e030g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005719.e030" xlink:type="simple"/>
<mml:math display="inline" id="M30">
<mml:mrow>
<mml:msubsup>
<mml:mi>ρ</mml:mi>
<mml:mrow>
<mml:mrow>
<mml:mo>[</mml:mo>
<mml:mrow>
<mml:mn>0</mml:mn>
<mml:mo>,</mml:mo>
<mml:mn>20</mml:mn>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
<mml:mo>♂</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</alternatives>
</inline-formula>
</td>
<td align="left">Reactivation rate in 0-20 year old males (<italic>yr</italic><sup>−1</sup>)</td>
<td align="char" char=".">0.0054</td>
<td align="center">0.0035—0.013</td>
</tr>
<tr>
<td align="right">
<inline-formula id="pcbi.1005719.e031">
<alternatives>
<graphic id="pcbi.1005719.e031g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005719.e031" xlink:type="simple"/>
<mml:math display="inline" id="M31">
<mml:mrow>
<mml:msubsup>
<mml:mi>ρ</mml:mi>
<mml:mrow>
<mml:mrow>
<mml:mo>[</mml:mo>
<mml:mrow>
<mml:mn>20</mml:mn>
<mml:mo>,</mml:mo>
<mml:mn>50</mml:mn>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
<mml:mo>♂</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</alternatives>
</inline-formula>
</td>
<td align="left">Reactivation rate in 20-50 year old males (<italic>yr</italic><sup>−1</sup>)</td>
<td align="char" char=".">0.011</td>
<td align="center">0.0035—0.018</td>
</tr>
<tr>
<td align="right">
<inline-formula id="pcbi.1005719.e005">
<alternatives>
<graphic id="pcbi.1005719.e005g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005719.e005" xlink:type="simple"/>
<mml:math display="inline" id="M5">
<mml:mrow>
<mml:msubsup>
<mml:mi>ρ</mml:mi>
<mml:mrow>
<mml:mrow>
<mml:mo>[</mml:mo>
<mml:mrow>
<mml:mn>50</mml:mn>
<mml:mo>,</mml:mo>
<mml:mn>80</mml:mn>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
<mml:mo>♂</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</alternatives>
</inline-formula>
</td>
<td align="left">Reactivation rate in 50-80 year old males (<italic>yr</italic><sup>−1</sup>)</td>
<td align="char" char=".">0.013</td>
<td align="center">0.0043—0.021</td>
</tr>
<tr>
<td align="right"><italic>μ</italic><sub><italic>ρ</italic></sub></td>
<td align="left">Hyperparameter for the reactivation rate (mean)</td>
<td align="char" char=".">0.015</td>
<td align="center">0.0047—0.027</td>
</tr>
<tr>
<td align="right"><italic>σ</italic><sub><italic>ρ</italic></sub></td>
<td align="left">Hyperparameter for the reactivation rate (sd)</td>
<td align="char" char=".">0.010</td>
<td align="center">0.0050—0.028</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t002fn001">
<p>Parameters estimates (represented by posterior medians with 95% credible intervals) are shown of the transmission model with reactivation and re-infection in the B compartment (model E). This model gives the best fit to the data, as judged by WBIC and WAIC (<xref ref-type="table" rid="pcbi.1005719.t001">Table 1</xref>). For all parameters the potential scale reduction factor <italic>Q</italic> is close to 1 (0.999 &lt; <italic>Q</italic> &lt; 1.001), and effective sample sizes of the parameters <italic>n</italic><sub>eff</sub> range from 3596 (<italic>β</italic><sub>1</sub>) to 4457 (<italic>μ</italic><sub><italic>ρ</italic></sub>).</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Estimates of the reactivation rates are quantitatively close in models with high support (Models E-F). Reactivation rates generally increase with increasing age, and are substantially higher in females than in males. In the preferred model (Model E), the estimated reactivation rate is 0.013 per year (95%CrI: 0.0042-0.021) in 0-20 year-old females, which increases to 0.021 per year (95%CrI: 0.013-0.029) in 20-50 year-old females, and then increases further to 0.028 per year (95%CrI: 0.017-0.040) in 50 + -year-old females (<xref ref-type="table" rid="pcbi.1005719.t002">Table 2</xref>). The corresponding reactivation rates in males are 0.0054 per year (95%CrI: 0.0035-0.013), 0.011 per year (95%CrI: 0.0035-0.018), and 0.013 per year (95%CrI: 0.0043-0.021). These estimates are slightly higher and slightly more precise in the model without re-infection (Model F), and somewhat higher in models with a single reactivation/re-infection event (Models A-B).</p>
<p>In the two models with highest support (Models E-F), estimates of the force of infection increase from approximately 0.012-0.013 per year in the youngest age group to 0.014-0.017 per year in 10-15 year-old girls (<xref ref-type="fig" rid="pcbi.1005719.g006">Fig 6</xref>). Owing to the slightly higher contact rates in females than in men, the estimated force of infection is usually slightly higher in females than in males in the age groups 10-25 years [<xref ref-type="bibr" rid="pcbi.1005719.ref032">32</xref>]. In older age groups, estimates of the forces of infection decrease to lower values (≈0.01 per year). Noteworthy, the extreme age-specific differences in the force of infection usually observed for directly transmitted infectious diseases, with high infection rates in children and much lower rates in adults, are much less pronounced here due to infectious reactivation in older age strata combined with age-assortative mixing [<xref ref-type="bibr" rid="pcbi.1005719.ref032">32</xref>, <xref ref-type="bibr" rid="pcbi.1005719.ref034">34</xref>, <xref ref-type="bibr" rid="pcbi.1005719.ref035">35</xref>].</p>
<fig id="pcbi.1005719.g006" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1005719.g006</object-id>
<label>Fig 6</label>
<caption>
<title>The force of infection and magnitude of reactivation relative to re-infection.</title>
<p>The top panel shows posterior estimates of the forces of infection in females and males in Model E (<xref ref-type="table" rid="pcbi.1005719.t001">Table 1</xref>; purple: females; brown: males). The bottom panel shows the log<sub>10</sub> of the reactivation rates divided by the re-infection rates (<italic>ρ</italic><sup><italic>i</italic></sup>(<italic>a</italic>)/<italic>zλ</italic><sup><italic>i</italic></sup>(<italic>a</italic>) with <italic>i</italic> ∈ {♀, ♂}). Results are shown for 250 samples from the posterior distribution.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005719.g006" xlink:type="simple"/>
</fig>
<p>In models with re-infection, estimates of re-infection rate (<italic>zλ</italic><sup><italic>i</italic></sup>(<italic>a</italic>)) are considerably smaller than estimates of the reactivation rates (<italic>ρ</italic><sup><italic>i</italic></sup>(<italic>a</italic>)) because the estimated forces of infection (λ<sup><italic>i</italic></sup>(<italic>a</italic>)) are usually lower than the reactivation rates, especially in females (<xref ref-type="fig" rid="pcbi.1005719.g006">Fig 6</xref>). Hence, re-infection contributes little to boosting of the antibody concentrations in those age groups where most of the boosting occurs (&gt;20 years; <xref ref-type="fig" rid="pcbi.1005719.g004">Fig 4</xref>). In fact, in adult females it is not uncommon that the reactivation rate is more than an order of magnitude higher than the estimated re-infection rate (log<sub>10</sub>(<italic>ρ</italic><sup>♀</sup>(<italic>a</italic>)/(<italic>zλ</italic><sup>♀</sup>(<italic>a</italic>))) &gt; 1).</p>
</sec>
</sec>
<sec id="sec014" sec-type="conclusions">
<title>Discussion</title>
<p>Our study of population-wide serological data shows that IgG antibody concentrations contain a wealth of information on the transmission dynamics of CMV. Specifically, the analyses reveal that (i) the prevalence of CMV increases gradually with age such that at old age the majority of persons in the Netherlands are infected; (ii) except for the very young, the prevalence of CMV is systematically higher in females than in males. This is mainly due to a higher incidence of infection in adult women than in adult men of similar age; (iii) antibody concentrations in seropositive (i.e. infected) persons increase monotonically with age, especially in women; (iv) the above findings (i)-(iii) cannot be explained by simple transmission models in which only primary infection is infectious. This is caused by the fact that transmissibility of primary infection determines the rate at which age-specific prevalence increases; if transmissibility of primary infection would be high then a high prevalence of infection is expected in children. In other words, the fact that seroprevalence increases gradually with age puts an upper bound on the force of infection, and this in turn constrains the transmissibility of primary infection to low values.</p>
<p>While aforementioned findings (i)-(iii) have been noticed before in other settings ([<xref ref-type="bibr" rid="pcbi.1005719.ref001">1</xref>] and references therein, [<xref ref-type="bibr" rid="pcbi.1005719.ref021">21</xref>]), our analyses are the first to provide precise estimates using a large population sample. Moreover, the results lead us to a new transmission hypothesis in which infectious reactivation is a key driver of transmission of CMV in the population. Since several other studies have found a gradual increase in seroprevalence [<xref ref-type="bibr" rid="pcbi.1005719.ref001">1</xref>], this explanation may not be restricted to the Dutch situation, but hold in general. Underpinning this hypothesis, next to the well-known observations of shedding of CMV in breast milk and cervical material in the third trimester of pregnancy [<xref ref-type="bibr" rid="pcbi.1005719.ref045">45</xref>–<xref ref-type="bibr" rid="pcbi.1005719.ref047">47</xref>], detectable virus also has been found in healthy adults in one study [<xref ref-type="bibr" rid="pcbi.1005719.ref024">24</xref>], while in another study CMV DNA has been detected in urine of the majority of older persons [<xref ref-type="bibr" rid="pcbi.1005719.ref023">23</xref>].</p>
<p>The main implication is that the majority of CMV infections may not be caused by transmission among children after primary infection, even though levels of shedding can be high in infants [<xref ref-type="bibr" rid="pcbi.1005719.ref046">46</xref>, <xref ref-type="bibr" rid="pcbi.1005719.ref048">48</xref>], but rather by older persons who go through one or more reactivation episodes. This contrasts with common childhood diseases such as measles, mumps, rubella, and pertussis. For these pathogens, infection in unvaccinated populations generally occurs at a young age, and children are the drivers of transmission. It also contrasts with other herpes viruses such as varicella zoster virus and Epstein-Bar virus for which well over 50% of the population is infected at the age of 10 years [<xref ref-type="bibr" rid="pcbi.1005719.ref034">34</xref>]. It may be comparable with other herpes viruses such as HSV1 and HSV2, which show a slowly increasing age-specific seroprevalence [<xref ref-type="bibr" rid="pcbi.1005719.ref049">49</xref>]. A corollary is that persistence of CMV in the population is not possible with transmission from primary infected persons only, and is dependent on infectious reactivation. Currently, we are focusing on making this idea more precise by calculation of the basic reproduction number, and the reproduction numbers of perinatal transmission, primary infection, and reactivation [<xref ref-type="bibr" rid="pcbi.1005719.ref050">50</xref>]. This will help put bounds on the relative contribution of each of the transmission routes.</p>
<p>With infectious reactivation and perinatal infection being putative drivers of transmission, it is to be expected that elimination by vaccination may prove more difficult than for directly transmitted pathogens, as it will require the pool of latently infected persons to dwindle to zero by demographic turnover. This can take up to the lifetime of one generation, and perhaps more if vaccination cannot prevent perinatal transmission to infants who are too young for vaccination. Thus, a question is whether vaccination formulations and strategies exist that minimize the probability of transmission to young infants. This is all the more of importance as a main source of morbidity is by congenital infection, and the timescale on which reductions in congenital disease are expected determines the projected health impact of vaccination [<xref ref-type="bibr" rid="pcbi.1005719.ref051">51</xref>]. In this context, next to the ability of a vaccine to prevent infection it may perhaps be equally important that a vaccine is able to reduce the probability of reactivation. Such reductions are likely mediated by T-cell responses of the host, and several (but not all) vaccines under development are expected to induce boosting of T-cell immune responses [<xref ref-type="bibr" rid="pcbi.1005719.ref052">52</xref>–<xref ref-type="bibr" rid="pcbi.1005719.ref054">54</xref>].</p>
<p>A number of limitations and assumptions deserve scrutiny. First, the transmission model analyses assume that the population is in endemic equilibrium. For a single cross-sectional data set such as the one considered in the present study this assumption is unavoidable if one does not want to introduce additional parameters that cannot be estimated by the data. Reassuringly, the patterns of infection present in the serological data have been found in several serological studies carried out in high-income countries over the past decades [<xref ref-type="bibr" rid="pcbi.1005719.ref001">1</xref>]. Also, no systematic patterns of increasing or decreasing seroprevalence over time have been found, and this is further reason to believe that there have not been major changes in the epidemiology of CMV over time [<xref ref-type="bibr" rid="pcbi.1005719.ref001">1</xref>]. Second, we assume that antibody measurements not only give information on CMV infection status, but also whether or not reactivation or re-infection have taken place. Unfortunately, there is no direct empirical evidence confirming or falsifying this assumption, and this is an area where in-depth comparison of the infection and immune status of persons with low and high antibody concentrations is urgently needed. Third, the analyses assume that person-to-person transmission is proportional to observed human contact patterns [<xref ref-type="bibr" rid="pcbi.1005719.ref032">32</xref>, <xref ref-type="bibr" rid="pcbi.1005719.ref033">33</xref>]. Although this assumption is commonly made and has met with considerable success (e.g., [<xref ref-type="bibr" rid="pcbi.1005719.ref033">33</xref>, <xref ref-type="bibr" rid="pcbi.1005719.ref044">44</xref>, <xref ref-type="bibr" rid="pcbi.1005719.ref055">55</xref>, <xref ref-type="bibr" rid="pcbi.1005719.ref056">56</xref>]), it is conceivable that transmission of CMV does not abide by the social contact hypothesis, and that a more complex contact structure would be able to explain the patterns of seroprevalence in a simple transmission model. To investigate the impact of the contact structure, we have analyzed transmission models with a uniform contact structure, and found that models with infectious reactivation still provide the best fit to the data (ΔWAIC &gt; 100; <xref ref-type="sec" rid="sec010">Results</xref>). As a final limitation we would like to add that, in principle, it is conceivable that the data can be explained alternatively by an intricate interplay between variation in the susceptibility to infection in conjunction with age-specific variations in the strength of the antibody response. Alas, evidence for or against this hypothesis is lacking.</p>
<p>Our inferential analyses indicate that the transmissibility of primary infection is much lower than the transmissibility after reactivation. This seems to be at odds with the observation that prolonged and high-level virus shedding can occur in bodily fluids after primary infection in children [<xref ref-type="bibr" rid="pcbi.1005719.ref046">46</xref>, <xref ref-type="bibr" rid="pcbi.1005719.ref047">47</xref>]. However, it could be that transitions from the infected class to the infected class with increased antibodies are in effect not the result of a single reactivation or re-infection event, but rather the result of multiple underlying reactivations or re-infections. If this were true, as seems plausible, estimates of the reactivation and re-infection rates as well as the transmissibility of reactivation and re-infection should be interpreted as compound parameters that take into account multiple reactivations and re-infections occurring over the lifetime of an infected person.</p>
</sec>
</body>
<back>
<ack>
<p>We thank Sophia de Jong (VU University Amsterdam) and Can Keşmir (Utrecht University) for discussion and critical reading, and the persons included in the PIENTER2 study for their participation.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pcbi.1005719.ref001">
<label>1</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Cannon</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Schmid</surname> <given-names>DS</given-names></name>, <name name-style="western"><surname>Hyde</surname> <given-names>TB</given-names></name>. <article-title>Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection</article-title>. <source>Rev Med Virol</source>. <year>2010</year>;<volume>20</volume>(<issue>4</issue>):<fpage>202</fpage>–<lpage>213</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/rmv.655" xlink:type="simple">10.1002/rmv.655</ext-link></comment> <object-id pub-id-type="pmid">20564615</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref002">
<label>2</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Dollard</surname> <given-names>SC</given-names></name>, <name name-style="western"><surname>Grosse</surname> <given-names>SD</given-names></name>, <name name-style="western"><surname>Ross</surname> <given-names>DS</given-names></name>. <article-title>New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection</article-title>. <source>Rev Med Virol</source>. <year>2007</year>;<volume>17</volume>(<issue>5</issue>):<fpage>355</fpage>–<lpage>363</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/rmv.544" xlink:type="simple">10.1002/rmv.544</ext-link></comment> <object-id pub-id-type="pmid">17542052</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref003">
<label>3</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Kenneson</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Cannon</surname> <given-names>MJ</given-names></name>. <article-title>Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection</article-title>. <source>Rev Med Virol</source>. <year>2007</year>;<volume>17</volume>(<issue>4</issue>):<fpage>253</fpage>–<lpage>276</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/rmv.535" xlink:type="simple">10.1002/rmv.535</ext-link></comment> <object-id pub-id-type="pmid">17579921</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref004">
<label>4</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Griffiths</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Plotkin</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Mocarski</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Pass</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Schleiss</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Krause</surname> <given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Desirability and feasibility of a vaccine against cytomegalovirus</article-title>. <source>Vaccine</source>. <year>2013</year>;<volume>31</volume> <issue>Suppl 2</issue>:<fpage>197</fpage>–<lpage>203</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.vaccine.2012.10.074" xlink:type="simple">10.1016/j.vaccine.2012.10.074</ext-link></comment></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref005">
<label>5</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Ramanan</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Razonable</surname> <given-names>RR</given-names></name>. <article-title>Cytomegalovirus infections in solid organ transplantation: a review</article-title>. <source>Infect Chemother</source>. <year>2013</year>;<volume>45</volume>(<issue>3</issue>):<fpage>260</fpage>–<lpage>271</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3947/ic.2013.45.3.260" xlink:type="simple">10.3947/ic.2013.45.3.260</ext-link></comment> <object-id pub-id-type="pmid">24396627</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref006">
<label>6</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Roberts</surname> <given-names>ET</given-names></name>, <name name-style="western"><surname>Haan</surname> <given-names>MN</given-names></name>, <name name-style="western"><surname>Dowd</surname> <given-names>JB</given-names></name>, <name name-style="western"><surname>Aiello</surname> <given-names>AE</given-names></name>. <article-title>Cytomegalovirus antibody levels, inflammation, and mortality among elderly Latinos over 9 years of follow-up</article-title>. <source>Am J Epidemiol</source>. <year>2010</year>;<volume>172</volume>(<issue>4</issue>):<fpage>363</fpage>–<lpage>371</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/aje/kwq177" xlink:type="simple">10.1093/aje/kwq177</ext-link></comment> <object-id pub-id-type="pmid">20660122</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref007">
<label>7</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Gkrania-Klotsas</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Langenberg</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Sharp</surname> <given-names>SJ</given-names></name>, <name name-style="western"><surname>Luben</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Khaw</surname> <given-names>KT</given-names></name>, <name name-style="western"><surname>Wareham</surname> <given-names>NJ</given-names></name>. <article-title>Higher immunoglobulin G antibody levels against cytomegalovirus are associated with incident ischemic heart disease in the population-based EPIC-Norfolk cohort</article-title>. <source>J Infect Dis</source>. <year>2012</year>;<volume>206</volume>(<issue>12</issue>):<fpage>1897</fpage>–<lpage>1903</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/infdis/jis620" xlink:type="simple">10.1093/infdis/jis620</ext-link></comment> <object-id pub-id-type="pmid">23045624</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref008">
<label>8</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Boeckh</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Geballe</surname> <given-names>AP</given-names></name>. <article-title>Cytomegalovirus: pathogen, paradigm, and puzzle</article-title>. <source>J Clin Invest</source>. <year>2011</year>;<volume>121</volume>(<issue>5</issue>):<fpage>1673</fpage>–<lpage>1680</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1172/JCI45449" xlink:type="simple">10.1172/JCI45449</ext-link></comment> <object-id pub-id-type="pmid">21659716</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref009">
<label>9</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Pawelec</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Derhovanessian</surname> <given-names>E</given-names></name>. <article-title>Role of CMV in immune senescence</article-title>. <source>Virus Res</source>. <year>2011</year>;<volume>157</volume>(<issue>2</issue>):<fpage>175</fpage>–<lpage>179</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.virusres.2010.09.010" xlink:type="simple">10.1016/j.virusres.2010.09.010</ext-link></comment> <object-id pub-id-type="pmid">20869407</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref010">
<label>10</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Pawelec</surname> <given-names>G</given-names></name>. <article-title>Immunosenenescence: role of cytomegalovirus</article-title>. <source>Exp Gerontol</source>. <year>2014</year>;<volume>54</volume>:<fpage>1</fpage>–<lpage>5</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.exger.2013.11.010" xlink:type="simple">10.1016/j.exger.2013.11.010</ext-link></comment> <object-id pub-id-type="pmid">24291068</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref011">
<label>11</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Sansoni</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Vescovini</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Fagnoni</surname> <given-names>FF</given-names></name>, <name name-style="western"><surname>Akbar</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Arens</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Chiu</surname> <given-names>YL</given-names></name>, <etal>et al</etal>. <article-title>New advances in CMV and immunosenescence</article-title>. <source>Exp Gerontol</source>. <year>2014</year>;<volume>55</volume>:<fpage>54</fpage>–<lpage>62</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.exger.2014.03.020" xlink:type="simple">10.1016/j.exger.2014.03.020</ext-link></comment> <object-id pub-id-type="pmid">24703889</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref012">
<label>12</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Klenerman</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Oxenius</surname> <given-names>A</given-names></name>. <article-title>T cell responses to cytomegalovirus</article-title>. <source>Nat Rev Immunol</source>. <year>2016</year>;<volume>16</volume>(<issue>6</issue>):<fpage>367</fpage>–<lpage>377</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nri.2016.38" xlink:type="simple">10.1038/nri.2016.38</ext-link></comment> <object-id pub-id-type="pmid">27108521</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref013">
<label>13</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Derhovanessian</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Maier</surname> <given-names>AB</given-names></name>, <name name-style="western"><surname>Hahnel</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>McElhaney</surname> <given-names>JE</given-names></name>, <name name-style="western"><surname>Slagboom</surname> <given-names>EP</given-names></name>, <name name-style="western"><surname>Pawelec</surname> <given-names>G</given-names></name>. <article-title>Latent infection with cytomegalovirus is associated with poor memory CD4 responses to influenza A core proteins in the elderly</article-title>. <source>J Immunol</source>. <year>2014</year>;<volume>193</volume>(<issue>7</issue>):<fpage>3624</fpage>–<lpage>3631</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.4049/jimmunol.1303361" xlink:type="simple">10.4049/jimmunol.1303361</ext-link></comment> <object-id pub-id-type="pmid">25187662</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref014">
<label>14</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Frasca</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Diaz</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Romero</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Landin</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Blomberg</surname> <given-names>BB</given-names></name>. <article-title>Cytomegalovirus (CMV) seropositivity decreases B cell responses to the influenza vaccine</article-title>. <source>Vaccine</source>. <year>2015</year>;<volume>33</volume>(<issue>12</issue>):<fpage>1433</fpage>–<lpage>1439</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.vaccine.2015.01.071" xlink:type="simple">10.1016/j.vaccine.2015.01.071</ext-link></comment> <object-id pub-id-type="pmid">25659271</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref015">
<label>15</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Frasca</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Blomberg</surname> <given-names>BB</given-names></name>. <article-title>Aging, cytomegalovirus (CMV) and influenza vaccine responses</article-title>. <source>Hum Vaccin Immunother</source>. <year>2016</year>;<volume>12</volume>(<issue>3</issue>):<fpage>682</fpage>–<lpage>690</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1080/21645515.2015.1105413" xlink:type="simple">10.1080/21645515.2015.1105413</ext-link></comment> <object-id pub-id-type="pmid">26588038</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref016">
<label>16</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Sung</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Schleiss</surname> <given-names>MR</given-names></name>. <article-title>Update on the current status of cytomegalovirus vaccines</article-title>. <source>Expert Rev Vaccines</source>. <year>2010</year>;<volume>9</volume>(<issue>11</issue>):<fpage>1303</fpage>–<lpage>1314</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1586/erv.10.125" xlink:type="simple">10.1586/erv.10.125</ext-link></comment> <object-id pub-id-type="pmid">21087108</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref017">
<label>17</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Plotkin</surname> <given-names>S</given-names></name>. <article-title>The history of vaccination against cytomegalovirus</article-title>. <source>Med Microbiol Immunol</source>. <year>2015</year>;<volume>204</volume>(<issue>3</issue>):<fpage>247</fpage>–<lpage>254</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00430-015-0388-z" xlink:type="simple">10.1007/s00430-015-0388-z</ext-link></comment> <object-id pub-id-type="pmid">25791890</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref018">
<label>18</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Staras</surname> <given-names>SA</given-names></name>, <name name-style="western"><surname>Dollard</surname> <given-names>SC</given-names></name>, <name name-style="western"><surname>Radford</surname> <given-names>KW</given-names></name>, <name name-style="western"><surname>Flanders</surname> <given-names>WD</given-names></name>, <name name-style="western"><surname>Pass</surname> <given-names>RF</given-names></name>, <name name-style="western"><surname>Cannon</surname> <given-names>MJ</given-names></name>. <article-title>Seroprevalence of cytomegalovirus infection in the United States, 1988-1994</article-title>. <source>Clin Infect Dis</source>. <year>2006</year>;<volume>43</volume>(<issue>9</issue>):<fpage>1143</fpage>–<lpage>1151</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1086/508173" xlink:type="simple">10.1086/508173</ext-link></comment> <object-id pub-id-type="pmid">17029132</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref019">
<label>19</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Staras</surname> <given-names>SA</given-names></name>, <name name-style="western"><surname>Flanders</surname> <given-names>WD</given-names></name>, <name name-style="western"><surname>Dollard</surname> <given-names>SC</given-names></name>, <name name-style="western"><surname>Pass</surname> <given-names>RF</given-names></name>, <name name-style="western"><surname>McGowan</surname> <given-names>JE</given-names></name>, <name name-style="western"><surname>Cannon</surname> <given-names>MJ</given-names></name>. <article-title>Cytomegalovirus seroprevalence and childhood sources of infection: A population-based study among pre-adolescents in the United States</article-title>. <source>J Clin Virol</source>. <year>2008</year>;<volume>43</volume>(<issue>3</issue>):<fpage>266</fpage>–<lpage>271</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jcv.2008.07.012" xlink:type="simple">10.1016/j.jcv.2008.07.012</ext-link></comment> <object-id pub-id-type="pmid">18778968</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref020">
<label>20</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Bate</surname> <given-names>SL</given-names></name>, <name name-style="western"><surname>Dollard</surname> <given-names>SC</given-names></name>, <name name-style="western"><surname>Cannon</surname> <given-names>MJ</given-names></name>. <article-title>Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988-2004</article-title>. <source>Clin Infect Dis</source>. <year>2010</year>;<volume>50</volume>(<issue>11</issue>):<fpage>1439</fpage>–<lpage>1447</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1086/652438" xlink:type="simple">10.1086/652438</ext-link></comment> <object-id pub-id-type="pmid">20426575</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref021">
<label>21</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Korndewal</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Mollema</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Tcherniaeva</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>van der Klis</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Kroes</surname> <given-names>AC</given-names></name>, <name name-style="western"><surname>Oudesluys-Murphy</surname> <given-names>AM</given-names></name>, <etal>et al</etal>. <article-title>Cytomegalovirus infection in the Netherlands: seroprevalence, risk factors, and implications</article-title>. <source>J Clin Virol</source>. <year>2015</year>;<volume>63</volume>:<fpage>53</fpage>–<lpage>58</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jcv.2014.11.033" xlink:type="simple">10.1016/j.jcv.2014.11.033</ext-link></comment> <object-id pub-id-type="pmid">25600606</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref022">
<label>22</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Aberle</surname> <given-names>JH</given-names></name>, <name name-style="western"><surname>Puchhammer-Stockl</surname> <given-names>E</given-names></name>. <article-title>Age-dependent increase of memory B cell response to cytomegalovirus in healthy adults</article-title>. <source>Exp Gerontol</source>. <year>2012</year>;<volume>47</volume>(<issue>8</issue>):<fpage>654</fpage>–<lpage>657</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.exger.2012.04.008" xlink:type="simple">10.1016/j.exger.2012.04.008</ext-link></comment> <object-id pub-id-type="pmid">22564865</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref023">
<label>23</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Stowe</surname> <given-names>RP</given-names></name>, <name name-style="western"><surname>Kozlova</surname> <given-names>EV</given-names></name>, <name name-style="western"><surname>Yetman</surname> <given-names>DL</given-names></name>, <name name-style="western"><surname>Walling</surname> <given-names>DM</given-names></name>, <name name-style="western"><surname>Goodwin</surname> <given-names>JS</given-names></name>, <name name-style="western"><surname>Glaser</surname> <given-names>R</given-names></name>. <article-title>Chronic herpesvirus reactivation occurs in aging</article-title>. <source>Exp Gerontol</source>. <year>2007</year>;<volume>42</volume>(<issue>6</issue>):<fpage>563</fpage>–<lpage>570</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.exger.2007.01.005" xlink:type="simple">10.1016/j.exger.2007.01.005</ext-link></comment> <object-id pub-id-type="pmid">17337145</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref024">
<label>24</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Parry</surname> <given-names>HM</given-names></name>, <name name-style="western"><surname>Zuo</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Frumento</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Mirajkar</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Inman</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Edwards</surname> <given-names>E</given-names></name>, <etal>et al</etal>. <article-title>Cytomegalovirus viral load within blood increases markedly in healthy people over the age of 70 years</article-title>. <source>Immun Ageing</source>. <year>2016</year>;<volume>13</volume>:<fpage>1</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/s12979-015-0056-6" xlink:type="simple">10.1186/s12979-015-0056-6</ext-link></comment> <object-id pub-id-type="pmid">26734066</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref025">
<label>25</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Alonso Arias</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Moro-Garcia</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Echeverria</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Solano-Jaurrieta</surname> <given-names>JJ</given-names></name>, <name name-style="western"><surname>Suarez-Garcia</surname> <given-names>FM</given-names></name>, <name name-style="western"><surname>Lopez-Larrea</surname> <given-names>C</given-names></name>. <article-title>Intensity of the humoral response to cytomegalovirus is associated with the phenotypic and functional status of the immune system</article-title>. <source>J Virol</source>. <year>2013</year>;<volume>87</volume>(<issue>8</issue>):<fpage>4486</fpage>–<lpage>4495</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/JVI.02425-12" xlink:type="simple">10.1128/JVI.02425-12</ext-link></comment> <object-id pub-id-type="pmid">23388717</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref026">
<label>26</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>de Bourcy</surname> <given-names>CF</given-names></name>, <name name-style="western"><surname>Angel</surname> <given-names>CJ</given-names></name>, <name name-style="western"><surname>Vollmers</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Dekker</surname> <given-names>CL</given-names></name>, <name name-style="western"><surname>Davis</surname> <given-names>MM</given-names></name>, <name name-style="western"><surname>Quake</surname> <given-names>SR</given-names></name>. <article-title>Phylogenetic analysis of the human antibody repertoire reveals quantitative signatures of immune senescence and aging</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2017</year>;<volume>114</volume>(<issue>5</issue>):<fpage>1105</fpage>–<lpage>1110</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1073/pnas.1617959114" xlink:type="simple">10.1073/pnas.1617959114</ext-link></comment> <object-id pub-id-type="pmid">28096374</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref027">
<label>27</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>van der Klis</surname> <given-names>FR</given-names></name>, <name name-style="western"><surname>Mollema</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Berbers</surname> <given-names>GA</given-names></name>, <name name-style="western"><surname>de Melker</surname> <given-names>HE</given-names></name>, <name name-style="western"><surname>Coutinho</surname> <given-names>RA</given-names></name>. <article-title>Second national serum bank for population-based seroprevalence studies in the Netherlands</article-title>. <source>Netherlands Journal of Medicine</source>. <year>2009</year>;<volume>67</volume>:<fpage>301</fpage>–<lpage>8</lpage>. <object-id pub-id-type="pmid">19687529</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref028">
<label>28</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Plummer</surname> <given-names>M</given-names></name>. <source>JAGS: A program for analysis of Bayesian graphical models using Gibbs sampling</source>; <year>2003</year>.</mixed-citation>
</ref>
<ref id="pcbi.1005719.ref029">
<label>29</label>
<mixed-citation publication-type="book" xlink:type="simple">
<collab>R Core Team</collab>. <source>R: A Language and Environment for Statistical Computing</source>; <year>2016</year>. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.R-project.org/" xlink:type="simple">https://www.R-project.org/</ext-link>.</mixed-citation>
</ref>
<ref id="pcbi.1005719.ref030">
<label>30</label>
<mixed-citation publication-type="book" xlink:type="simple">
<name name-style="western"><surname>Diekmann</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Heesterbeek</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Britton</surname> <given-names>T</given-names></name>. <source>Mathematical Tools for Understanding Infectious Disease Dynamics</source>. <publisher-name>Princeton University Press</publisher-name>; <year>2013</year>.</mixed-citation>
</ref>
<ref id="pcbi.1005719.ref031">
<label>31</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Farrington</surname> <given-names>CP</given-names></name>, <name name-style="western"><surname>Whitaker</surname> <given-names>HJ</given-names></name>. <article-title>Estimation of effective reproduction numbers for infectious diseases using serological survey data</article-title>. <source>Biostatistics</source>. <year>2003</year>;<volume>4</volume>(<issue>4</issue>):<fpage>621</fpage>–<lpage>632</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/biostatistics/4.4.621" xlink:type="simple">10.1093/biostatistics/4.4.621</ext-link></comment> <object-id pub-id-type="pmid">14557115</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref032">
<label>32</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>van de Kassteele</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>van Eijkeren</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Wallinga</surname> <given-names>J</given-names></name>. <article-title>Efficient estimation of age-specific social contact rates between men and women</article-title>. <source>Annals of Applied Statistics</source>. <year>2017</year>;<volume>11</volume>:<fpage>320</fpage>–<lpage>339</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1214/16-AOAS1006" xlink:type="simple">10.1214/16-AOAS1006</ext-link></comment></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref033">
<label>33</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Mossong</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Hens</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Jit</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Beutels</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Auranen</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Mikolajczyk</surname> <given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Social contacts and mixing patterns relevant to the spread of infectious diseases</article-title>. <source>PLOS Medicine</source>. <year>2008</year>;<volume>5</volume>:<fpage>e74</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pmed.0050074" xlink:type="simple">10.1371/journal.pmed.0050074</ext-link></comment> <object-id pub-id-type="pmid">18366252</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref034">
<label>34</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>van Lier</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Lugner</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Opstelten</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Jochemsen</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Wallinga</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Schellevis</surname> <given-names>F</given-names></name>, <etal>et al</etal>. <article-title>Distribution of Health Effects and Cost-effectiveness of Varicella Vaccination are Shaped by the Impact on Herpes Zoster</article-title>. <source>EBioMedicine</source>. <year>2015</year>;<volume>2</volume>(<issue>10</issue>):<fpage>1494</fpage>–<lpage>1499</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ebiom.2015.08.017" xlink:type="simple">10.1016/j.ebiom.2015.08.017</ext-link></comment> <object-id pub-id-type="pmid">26629544</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref035">
<label>35</label>
<mixed-citation publication-type="book" xlink:type="simple">
<name name-style="western"><surname>Hens</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Shkedy</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Aerts</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Faes</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Van Damme</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Beutels</surname> <given-names>P</given-names></name>. <source>Modeling Infectious Disease Parameters Based on Serological and Social Contact Data</source>. <publisher-name>Springer</publisher-name> <publisher-loc>New York</publisher-loc>; <year>2012</year>.</mixed-citation>
</ref>
<ref id="pcbi.1005719.ref036">
<label>36</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Goeyvaerts</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Hens</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Ogunjimi</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Aerts</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Shkedy</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>van Damme</surname> <given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Estimating infectious disease parameters from data on social contacts and serological status</article-title>. <source>Journal of the Royal Statistical Society: Series C (Applied Statistics)</source>. <year>2010</year>;<volume>59</volume>(<issue>2</issue>):<fpage>255</fpage>–<lpage>277</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1467-9876.2009.00693.x" xlink:type="simple">10.1111/j.1467-9876.2009.00693.x</ext-link></comment></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref037">
<label>37</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Goeyvaerts</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Hens</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Aerts</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Beutels</surname> <given-names>P</given-names></name>. <article-title>Model structure analysis to estimate basic immunological processes and maternal risk for parvovirus B19</article-title>. <source>Biostatistics (Oxford, England)</source>. <year>2011</year>;<volume>12</volume>(<issue>2</issue>):<fpage>283</fpage>–<lpage>302</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/biostatistics/kxq059" xlink:type="simple">10.1093/biostatistics/kxq059</ext-link></comment></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref038">
<label>38</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Gelman</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Rubin</surname> <given-names>DB</given-names></name>. <article-title>Inference from iterative simulation using multiple sequences</article-title>. <source>Statistical Science</source>. <year>1992</year>;<volume>7</volume>(<issue>4</issue>):<fpage>457</fpage>–<lpage>472</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1214/ss/1177011136" xlink:type="simple">10.1214/ss/1177011136</ext-link></comment></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref039">
<label>39</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Watanabe</surname> <given-names>S</given-names></name>. <article-title>A widely applicable Bayesian information criterion</article-title>. <source>Journal of Machine Learning Research</source>. <year>2013</year>;<volume>14</volume>:<fpage>867</fpage>–<lpage>897</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1005719.ref040">
<label>40</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Piironen</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Vehtari</surname> <given-names>A</given-names></name>. <article-title>Comparison of Bayesian predictive methods for model selection</article-title>. <source>Statistics and Computing</source>. <year>2016</year>; p. <fpage>1</fpage>–<lpage>25</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1005719.ref041">
<label>41</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Vehtari</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Gelman</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Gabry</surname> <given-names>J</given-names></name>. <article-title>Practical Bayesian model evaluation using leave-one-out cross-validation and WAIC</article-title>. <source>Statistics and Computing</source>. <year>2016</year>; in press.</mixed-citation>
</ref>
<ref id="pcbi.1005719.ref042">
<label>42</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Steens</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Waaijenborg</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Teunis</surname> <given-names>PF</given-names></name>, <name name-style="western"><surname>Reimerink</surname> <given-names>JH</given-names></name>, <name name-style="western"><surname>Meijer</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>van der Lubben</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Age-dependent patterns of infection and severity explaining the low impact of 2009 influenza A (H1N1): evidence from serial serologic surveys in the Netherlands</article-title>. <source>Am J Epidemiol</source>. <year>2011</year>;<volume>174</volume>(<issue>11</issue>):<fpage>1307</fpage>–<lpage>1315</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/aje/kwr245" xlink:type="simple">10.1093/aje/kwr245</ext-link></comment> <object-id pub-id-type="pmid">22025354</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref043">
<label>43</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>te Beest</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>de Bruin</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Imholz</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Wallinga</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Teunis</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Koopmans</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Discrimination of influenza infection (A/2009 H1N1) from prior exposure by antibody protein microarray analysis</article-title>. <source>PLoS ONE</source>. <year>2014</year>;<volume>9</volume>(<issue>11</issue>):<fpage>e113021</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0113021" xlink:type="simple">10.1371/journal.pone.0113021</ext-link></comment> <object-id pub-id-type="pmid">25405997</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref044">
<label>44</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>te Beest</surname> <given-names>DE</given-names></name>, <name name-style="western"><surname>Birrell</surname> <given-names>PJ</given-names></name>, <name name-style="western"><surname>Wallinga</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>De Angelis</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>van Boven</surname> <given-names>M</given-names></name>. <article-title>Joint modelling of serological and hospitalization data reveals that high levels of pre-existing immunity and school holidays shaped the influenza A pandemic of 2009 in the Netherlands</article-title>. <source>J R Soc Interface</source>. <year>2015</year>;<volume>12</volume>(<issue>103</issue>). <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1098/rsif.2014.1244" xlink:type="simple">10.1098/rsif.2014.1244</ext-link></comment> <object-id pub-id-type="pmid">25540241</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref045">
<label>45</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Hamprecht</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Maschmann</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Vochem</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Dietz</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Speer</surname> <given-names>CP</given-names></name>, <name name-style="western"><surname>Jahn</surname> <given-names>G</given-names></name>. <article-title>Epidemiology of transmission of cytomegalovirus from mother to preterm infant by breastfeeding</article-title>. <source>Lancet</source>. <year>2001</year>;<volume>357</volume>(<issue>9255</issue>):<fpage>513</fpage>–<lpage>518</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0140-6736(00)04043-5" xlink:type="simple">10.1016/S0140-6736(00)04043-5</ext-link></comment> <object-id pub-id-type="pmid">11229670</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref046">
<label>46</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Cannon</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Hyde</surname> <given-names>TB</given-names></name>, <name name-style="western"><surname>Schmid</surname> <given-names>DS</given-names></name>. <article-title>Review of cytomegalovirus shedding in bodily fluids and relevance to congenital cytomegalovirus infection</article-title>. <source>Rev Med Virol</source>. <year>2011</year>;<volume>21</volume>(<issue>4</issue>):<fpage>240</fpage>–<lpage>255</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/rmv.695" xlink:type="simple">10.1002/rmv.695</ext-link></comment> <object-id pub-id-type="pmid">21674676</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref047">
<label>47</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Pass</surname> <given-names>RF</given-names></name>, <name name-style="western"><surname>Anderson</surname> <given-names>B</given-names></name>. <article-title>Mother-to-Child Transmission of Cytomegalovirus and Prevention of Congenital Infection</article-title>. <source>J Pediatric Infect Dis Soc</source>. <year>2014</year>;<volume>3</volume> <issue>Suppl 1</issue>:<fpage>2</fpage>–<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/jpids/piu069" xlink:type="simple">10.1093/jpids/piu069</ext-link></comment></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref048">
<label>48</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Cannon</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Stowell</surname> <given-names>JD</given-names></name>, <name name-style="western"><surname>Clark</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Dollard</surname> <given-names>PR</given-names></name>, <name name-style="western"><surname>Johnson</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Mask</surname> <given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Repeated measures study of weekly and daily cytomegalovirus shedding patterns in saliva and urine of healthy cytomegalovirus-seropositive children</article-title>. <source>BMC Infect Dis</source>. <year>2014</year>;<volume>14</volume>:<fpage>569</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/s12879-014-0569-1" xlink:type="simple">10.1186/s12879-014-0569-1</ext-link></comment> <object-id pub-id-type="pmid">25391640</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref049">
<label>49</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Woestenberg</surname> <given-names>PJ</given-names></name>, <name name-style="western"><surname>Tjhie</surname> <given-names>JH</given-names></name>, <name name-style="western"><surname>de Melker</surname> <given-names>HE</given-names></name>, <name name-style="western"><surname>van der Klis</surname> <given-names>FR</given-names></name>, <name name-style="western"><surname>van Bergen</surname> <given-names>JE</given-names></name>, <name name-style="western"><surname>van der Sande</surname> <given-names>MA</given-names></name>, <etal>et al</etal>. <article-title>Herpes simplex virus type 1 and type 2 in the Netherlands: seroprevalence, risk factors and changes during a 12-year period</article-title>. <source>BMC Infect Dis</source>. <year>2016</year>;<volume>16</volume>:<fpage>364</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/s12879-016-1707-8" xlink:type="simple">10.1186/s12879-016-1707-8</ext-link></comment> <object-id pub-id-type="pmid">27484304</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref050">
<label>50</label>
<mixed-citation publication-type="other" xlink:type="simple">de Jong S. Estimation of Perinatal Transmission Rates of Cytomegalovirus From Serological Data and Calculation of Reproduction Numbers. MSc thesis, VU University Amsterdam; 2017.</mixed-citation>
</ref>
<ref id="pcbi.1005719.ref051">
<label>51</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Korndewal</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Vossen</surname> <given-names>AC</given-names></name>, <name name-style="western"><surname>Cremer</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>VAN Binnendijk</surname> <given-names>RS</given-names></name>, <name name-style="western"><surname>Kroes</surname> <given-names>AC</given-names></name>, <name name-style="western"><surname>van der Sande</surname> <given-names>MA</given-names></name>, <etal>et al</etal>. <article-title>Disease burden of congenital cytomegalovirus infection at school entry age: study design, participation rate and birth prevalence</article-title>. <source>Epidemiol Infect</source>. <year>2016</year>;<volume>144</volume>(<issue>7</issue>):<fpage>1520</fpage>–<lpage>1527</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1017/S0950268815002708" xlink:type="simple">10.1017/S0950268815002708</ext-link></comment> <object-id pub-id-type="pmid">26554756</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref052">
<label>52</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Sabbaj</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Pass</surname> <given-names>RF</given-names></name>, <name name-style="western"><surname>Goepfert</surname> <given-names>PA</given-names></name>, <name name-style="western"><surname>Pichon</surname> <given-names>S</given-names></name>. <article-title>Glycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women</article-title>. <source>J Infect Dis</source>. <year>2011</year>;<volume>203</volume>(<issue>11</issue>):<fpage>1534</fpage>–<lpage>1541</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/infdis/jir138" xlink:type="simple">10.1093/infdis/jir138</ext-link></comment> <object-id pub-id-type="pmid">21592981</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref053">
<label>53</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Bialas</surname> <given-names>KM</given-names></name>, <name name-style="western"><surname>Permar</surname> <given-names>SR</given-names></name>. <article-title>The March towards a Vaccine for Congenital CMV: Rationale and Models</article-title>. <source>PLoS Pathog</source>. <year>2016</year>;<volume>12</volume>(<issue>2</issue>):<fpage>e1005355</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.ppat.1005355" xlink:type="simple">10.1371/journal.ppat.1005355</ext-link></comment> <object-id pub-id-type="pmid">26866914</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref054">
<label>54</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Schleiss</surname> <given-names>MR</given-names></name>. <article-title>Preventing Congenital Cytomegalovirus Infection: Protection to a’T’</article-title>. <source>Trends Microbiol</source>. <year>2016</year>;<volume>24</volume>(<issue>3</issue>):<fpage>170</fpage>–<lpage>172</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.tim.2016.01.007" xlink:type="simple">10.1016/j.tim.2016.01.007</ext-link></comment> <object-id pub-id-type="pmid">26857178</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref055">
<label>55</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Wallinga</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Teunis</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Kretzschmar</surname> <given-names>M</given-names></name>. <article-title>Using data on social contacts to estimate age-specific transmission parameters for respiratory-spread infectious agents</article-title>. <source>Am J Epidemiol</source>. <year>2006</year>;<volume>164</volume>(<issue>10</issue>):<fpage>936</fpage>–<lpage>944</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/aje/kwj317" xlink:type="simple">10.1093/aje/kwj317</ext-link></comment> <object-id pub-id-type="pmid">16968863</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005719.ref056">
<label>56</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Goeyvaerts</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Willem</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Van Kerckhove</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Vandendijck</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Hanquet</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Beutels</surname> <given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Estimating dynamic transmission model parameters for seasonal influenza by fitting to age and season-specific influenza-like illness incidence</article-title>. <source>Epidemics</source>. <year>2015</year>;<volume>13</volume>:<fpage>1</fpage>–<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.epidem.2015.04.002" xlink:type="simple">10.1016/j.epidem.2015.04.002</ext-link></comment> <object-id pub-id-type="pmid">26616037</object-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>